{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":1303,"total_is_capped":false,"direct_labels_cover":3,"predictions_cover":1303,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"b1cf7d12156a","filters":{"topic":"HER2/EGFR in Cancer Research"}},"results":[{"id":"W2318605753","doi":"10.1056/nejm200103153441101","title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","year":2001,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11512,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Trastuzumab; Epirubicin; Anthracycline; Internal medicine; Breast cancer; Oncology; Cyclophosphamide; Chemotherapy; Doxorubicin; Metastatic breast cancer; Paclitaxel; Cancer; Gastroenterology","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Brian Leyland‐Jones","is_ca":true},{"name":"Steven Shak","is_ca":false},{"name":"H. Fuchs","is_ca":false},{"name":"Virginia Paton","is_ca":false},{"name":"Alex Bajamonde","is_ca":false},{"name":"Thomas Fleming","is_ca":false},{"name":"W. Eiermann","is_ca":false},{"name":"Janet Wolter","is_ca":false},{"name":"Mark D. Pegram","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Larry Norton","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1035786067360863,"gpt":0.4099576805019227,"spread":0.3063790737658363,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005369638,0.0003356146,0.0008390681,0.0003533569,0.0002226064,0.0001821425,0.0002903158,0.0003491369,0.001416809],"category_scores_gemma":[0.001643994,0.0001412686,0.0004193588,0.0002955903,0.0003335623,0.0001703751,0.0002415541,0.0005503112,0.0002051872],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000498793,"about_ca_system_score_gemma":0.0004934613,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00040331,"about_ca_topic_score_gemma":0.001168412,"domain_scores_codex":[0.9996462,0.0001197381,0.0000472175,0.00007252943,0.00006628254,0.00004814286],"domain_scores_gemma":[0.9989654,0.0004144843,0.0002387291,0.00008413076,0.00003834279,0.0002588757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1876869,0.01825456,0.1336202,0.00133779,0.00232194,0.0012692,0.0002920346,0.007941682,0.09358046,0.0006239227,0.0023629,0.5507085],"study_design_scores_gemma":[0.07531156,0.5644845,0.2811874,0.0004101758,0.00227368,0.006621256,0.0001188972,0.005788987,0.03450253,0.0005701912,0.02864737,0.00008345491],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948978,0.002763743,0.0005166555,0.0002225841,0.0001017672,0.0002740576,0.00007373931,0.00002431936,0.001125354],"genre_scores_gemma":[0.996989,0.001079167,0.0009193358,0.0001575154,0.00011535,0.0002120121,0.0001737044,0.000003912216,0.0003500027],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001416809,"threshold_uncertainty_score":0.004739702,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2149908785","doi":"10.1056/nejmoa052306","title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":5098,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; McGill University","funders":"","keywords":"Trastuzumab; Medicine; Breast cancer; Oncology; Chemotherapy; Adjuvant; Monoclonal antibody; Internal medicine; Adjuvant chemotherapy; Cancer; Stage (stratigraphy); Antibody; Immunology","authors":[{"name":"Martine Piccart","is_ca":false},{"name":"Marion Procter","is_ca":false},{"name":"Brian Leyland‐Jones","is_ca":true},{"name":"Aron Goldhirsch","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Ian Smith","is_ca":false},{"name":"Luca Gianni","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Richard H. Bell","is_ca":false},{"name":"Christian Jackisch","is_ca":false},{"name":"David Cameron","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Günther Steger","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Michael Andersson","is_ca":false},{"name":"Moshe Inbar","is_ca":false},{"name":"Mikhail Lichinitser","is_ca":false},{"name":"István Láng","is_ca":false},{"name":"Ulrike Nitz","is_ca":false},{"name":"Hiroji Iwata","is_ca":false},{"name":"Christoph Thomssen","is_ca":false},{"name":"Caroline Lohrisch","is_ca":true},{"name":"Thomas Suter","is_ca":false},{"name":"Josef Rüschoff","is_ca":false},{"name":"Tamás Sütö","is_ca":false},{"name":"Victoria Greatorex","is_ca":false},{"name":"Carol Ward","is_ca":false},{"name":"Carolyn Straehle","is_ca":false},{"name":"Eleanor McFadden","is_ca":false},{"name":"Mirko Dolci","is_ca":false},{"name":"Richard D. Gelber","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01611926741677746,"gpt":0.3460186708027299,"spread":0.3298994033859524,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001307874,0.0001884257,0.0005863534,0.0001775647,0.0001228341,0.0003011347,0.0002575014,0.0003418625,0.0008242241],"category_scores_gemma":[0.001487557,0.00007307741,0.0003483745,0.0003000795,0.0002208555,0.0002027053,0.0001897777,0.0006771703,0.00009323444],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003988289,"about_ca_system_score_gemma":0.0004413665,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000313991,"about_ca_topic_score_gemma":0.0006878774,"domain_scores_codex":[0.999585,0.0002423513,0.00002575208,0.00003484609,0.00005046497,0.00006155474],"domain_scores_gemma":[0.9993491,0.0002713102,0.0001822119,0.00004067579,0.00003107558,0.0001255307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4696186,0.009856511,0.04331169,0.001812999,0.001174904,0.0008342626,0.0002096251,0.005179894,0.02381461,0.0007855524,0.0029691,0.4404322],"study_design_scores_gemma":[0.3173281,0.4750189,0.1349772,0.0006439401,0.002776466,0.002126566,0.0001115352,0.005072367,0.02327482,0.00173319,0.03689735,0.00003958838],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837577,0.01402441,0.0002840728,0.0003107307,0.0001388052,0.0001727349,0.00006956055,0.00001028476,0.001231713],"genre_scores_gemma":[0.9949072,0.003584093,0.0002956689,0.0002170591,0.0001359794,0.0001868884,0.0001896194,0.000002787309,0.0004806323],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001307874,"threshold_uncertainty_score":0.006916761,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2159967578","doi":"10.1056/nejmoa1209124","title":"Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer","year":2012,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3784,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Trastuzumab emtansine; Trastuzumab; Antibody-drug conjugate; Medicine; Cytotoxic T cell; Metastatic breast cancer; Conjugate; Breast cancer; Oncology; Antibody; Linker; Cancer research; Cancer; Monoclonal antibody; Pharmacology; Internal medicine; Immunology; In vitro; Biology","authors":[{"name":"Sunil Verma","is_ca":true},{"name":"David Miles","is_ca":false},{"name":"Luca Gianni","is_ca":false},{"name":"Ian E. Krop","is_ca":false},{"name":"Manfred Welslau","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Mark D. Pegram","is_ca":false},{"name":"Do‐Youn Oh","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Ellie Guardino","is_ca":false},{"name":"Fang Ting Liang","is_ca":false},{"name":"Michael W. Lu","is_ca":false},{"name":"Steven R. Olsen","is_ca":false},{"name":"Kim T. Blackwell","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0357706020618461,"gpt":0.3903459424953969,"spread":0.3545753404335508,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001252512,0.0002049619,0.0006377842,0.0002286278,0.0001262074,0.0002486735,0.0001820591,0.0002379938,0.00220844],"category_scores_gemma":[0.001269592,0.0000620779,0.0003039495,0.0001897603,0.0001676973,0.0001428885,0.0001751295,0.0004034406,0.0002607927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004541817,"about_ca_system_score_gemma":0.0004450624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001707179,"about_ca_topic_score_gemma":0.0004663772,"domain_scores_codex":[0.9995201,0.0002830489,0.00004914189,0.00004874412,0.00006438853,0.00003466319],"domain_scores_gemma":[0.9996144,0.0001438251,0.000111136,0.00002223551,0.00002960258,0.00007883421],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1794291,0.003285172,0.0196005,0.003576882,0.001046056,0.000815886,0.0002049646,0.004192044,0.02989654,0.001285131,0.007085094,0.7495826],"study_design_scores_gemma":[0.3092201,0.2832177,0.141144,0.001833591,0.004356595,0.00910824,0.0002005469,0.009094613,0.04134228,0.005316231,0.1950686,0.00009758649],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9517747,0.03665848,0.00184132,0.00168505,0.0002738614,0.001427805,0.0003788438,0.00004560623,0.005914249],"genre_scores_gemma":[0.9864075,0.008929901,0.001537962,0.0006324224,0.0002217745,0.000512834,0.0003384818,0.00000675912,0.001412186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00220844,"threshold_uncertainty_score":0.007387996,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2098775844","doi":"10.1056/nejmoa0910383","title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2775,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; Genentech; Sanofi; Eli Lilly and Company; California Breast Cancer Research Program; GlaxoSmithKline; Amgen","keywords":"Trastuzumab; Medicine; Anthracycline; Internal medicine; Regimen; Docetaxel; Carboplatin; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Cancer; Chemotherapy; Surgery; Cisplatin","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"W. Eiermann","is_ca":false},{"name":"Nicholas J. Robert","is_ca":false},{"name":"Tadeusz Pieńkowski","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Michael F. Press","is_ca":false},{"name":"John R. Mackey","is_ca":true},{"name":"John A. Glaspy","is_ca":false},{"name":"Arlene Chan","is_ca":false},{"name":"Marek Pawlicki","is_ca":false},{"name":"Tamás Pintér","is_ca":false},{"name":"Vicente Valero","is_ca":false},{"name":"Mei-Ching Liu","is_ca":false},{"name":"Guido Sauter","is_ca":false},{"name":"Gϋnter von Minckwitz","is_ca":false},{"name":"F. Visco","is_ca":false},{"name":"Valerie Bée","is_ca":false},{"name":"Marc Buyse","is_ca":false},{"name":"Belguendouz Bendahmane","is_ca":false},{"name":"Isabelle Tabah-Fisch","is_ca":false},{"name":"Mary-Ann Lindsay","is_ca":false},{"name":"A. Riva","is_ca":false},{"name":"John Crown","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0562133101311759,"gpt":0.3561151897078348,"spread":0.2999018795766589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001163307,0.0001813685,0.000429489,0.000154084,0.0001334813,0.0002103996,0.0002009633,0.0002473008,0.0008360354],"category_scores_gemma":[0.001307852,0.00006882218,0.0001690013,0.0002810704,0.0001789658,0.000109069,0.0001794593,0.0003739279,0.00009968154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003495507,"about_ca_system_score_gemma":0.0004155653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002586246,"about_ca_topic_score_gemma":0.0005661273,"domain_scores_codex":[0.9996189,0.0002293155,0.00002924572,0.00002741294,0.00005624786,0.00003886163],"domain_scores_gemma":[0.9996713,0.0001538735,0.00006510439,0.0000216371,0.00002113566,0.00006705173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1766195,0.005950272,0.1232935,0.001955932,0.0006070483,0.002430128,0.0002476077,0.006026058,0.02444026,0.0009064924,0.004320547,0.6532027],"study_design_scores_gemma":[0.1433366,0.3184141,0.3670387,0.001219455,0.003499556,0.0128575,0.0002659805,0.01481479,0.0361521,0.004037728,0.09830144,0.00006205084],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841301,0.01307201,0.0004073814,0.0003222886,0.00007165442,0.0002002726,0.00008855273,0.000009574655,0.001698173],"genre_scores_gemma":[0.9940895,0.004275445,0.0004230076,0.0001962541,0.0001042976,0.0001846961,0.0001957288,0.000002022789,0.0005290947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001163307,"threshold_uncertainty_score":0.006152213,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281640394","doi":"10.1056/nejmoa2203690","title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2548,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; First Hospital of Jilin University; West China Hospital, Sichuan University; University of California, San Francisco; Kyungpook National University; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Peking Union Medical College; Cleveland Clinic; Samsung; Universitat de Barcelona; Seoul National University Hospital; College of Medicine, Seoul National University; Memorial Sloan-Kettering Cancer Center; Yonsei University; Chinese Academy of Medical Sciences; Tel Aviv University; Seoul National University; Jilin University; Liaoning Cancer Hospital and Institute; Sichuan University; Sun Yat-sen University; Queen Mary University of London; Cleveland Clinic Foundation; University of Ulsan; Institute of Genetics; AstraZeneca; Cancer Research Institute","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","authors":[{"name":"Shanu Modi","is_ca":false},{"name":"William Jacot","is_ca":false},{"name":"Toshinari Yamashita","is_ca":false},{"name":"Joohyuk Sohn","is_ca":false},{"name":"María Vidal","is_ca":false},{"name":"Eriko Tokunaga","is_ca":false},{"name":"Junji Tsurutani","is_ca":false},{"name":"Naoto T. Ueno","is_ca":false},{"name":"Aleix Prat","is_ca":false},{"name":"Yee Soo Chae","is_ca":false},{"name":"Keun Seok Lee","is_ca":false},{"name":"Naoki Niikura","is_ca":false},{"name":"Yeon Hee Park","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Xiaojia Wang","is_ca":false},{"name":"Miguel Gil‐Gil","is_ca":false},{"name":"Wěi Li","is_ca":false},{"name":"Jean‐Yves Pierga","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Halle C. F. Moore","is_ca":false},{"name":"Hope S. Rugo","is_ca":false},{"name":"Rinat Yerushalmi","is_ca":false},{"name":"Flora Zagouri","is_ca":false},{"name":"Andrea Gombos","is_ca":false},{"name":"Sung‐Bae Kim","is_ca":false},{"name":"Qiang Liu","is_ca":false},{"name":"Ting Luo","is_ca":false},{"name":"Cristina Saura","is_ca":false},{"name":"Peter Schmid","is_ca":false},{"name":"Tao Sun","is_ca":false},{"name":"Dhiraj Gambhire","is_ca":false},{"name":"Lotus Yung","is_ca":false},{"name":"Yibin Wang","is_ca":false},{"name":"Jasmeet Singh","is_ca":false},{"name":"Patrik Vitazka","is_ca":false},{"name":"Gerold Meinhardt","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"David Cameron","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0217942489314834,"gpt":0.3451216111915363,"spread":0.3233273622600529,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000747692,0.0002147558,0.0005839727,0.0001890448,0.0001638125,0.0002663486,0.0002045753,0.0002100705,0.0007599106],"category_scores_gemma":[0.0008621488,0.00009203891,0.0002300799,0.0002281592,0.0002411502,0.0001728678,0.0001665991,0.0004207446,0.0001033144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005760767,"about_ca_system_score_gemma":0.000468237,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005961757,"about_ca_topic_score_gemma":0.001715716,"domain_scores_codex":[0.9997281,0.0001587381,0.00001324057,0.00002972752,0.0000343667,0.00003587277],"domain_scores_gemma":[0.9996969,0.000106405,0.00006995906,0.00001344825,0.00000935901,0.0001039307],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4023675,0.01383734,0.1059474,0.0008019426,0.0015152,0.001298188,0.000377433,0.01110436,0.02960875,0.0006578915,0.004353354,0.4281307],"study_design_scores_gemma":[0.2066874,0.4292376,0.3138679,0.0002901442,0.001417515,0.003024501,0.0001801751,0.01158573,0.01267896,0.001505164,0.01947471,0.00005035645],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9967477,0.002451623,0.00007839432,0.000116628,0.00002548746,0.00005581088,0.00003704898,0.000006246889,0.0004808939],"genre_scores_gemma":[0.9975859,0.001458957,0.0002088814,0.0001580289,0.00004597697,0.00007262112,0.0001374746,0.000001872658,0.0003303069],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0007599106,"threshold_uncertainty_score":0.004179776,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2123591186","doi":"10.1016/s1470-2045(11)70336-9","title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2358,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"","keywords":"Pertuzumab; Trastuzumab; Docetaxel; Medicine; Internal medicine; Clinical endpoint; Breast cancer; Oncology; Population; Chemotherapy; Clinical trial; Cancer","authors":[{"name":"Luca Gianni","is_ca":false},{"name":"Tadeusz Pieńkowski","is_ca":false},{"name":"Young‐Hyuck Im","is_ca":false},{"name":"Laslo Roman","is_ca":false},{"name":"Ling‐Ming Tseng","is_ca":false},{"name":"Mei-Ching Liu","is_ca":false},{"name":"Aňa Lluch","is_ca":false},{"name":"Elżbieta Starosławska","is_ca":false},{"name":"Juan de la Haba-Rodríguez","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"José Luiz Pedrini","is_ca":false},{"name":"Brigitte Poirier","is_ca":true},{"name":"Paolo Morandi","is_ca":false},{"name":"Semiglazov Vf","is_ca":false},{"name":"Vichien Srimuninnimit","is_ca":false},{"name":"Giulia Bianchi","is_ca":false},{"name":"Tania Szado","is_ca":false},{"name":"Jayantha Ratnayake","is_ca":false},{"name":"Graham Ross","is_ca":false},{"name":"Pinuccia Valagussa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06039123479763487,"gpt":0.3881995916148677,"spread":0.3278083568172329,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753153,0.00178147,0.00227994,0.0003637272,0.0003305751,0.0009581393,0.00083788,0.002071146,0.005738767],"category_scores_gemma":[0.002160263,0.0008675606,0.001584232,0.0003744978,0.001581891,0.001523786,0.0005098716,0.003133686,0.00101437],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071718,"about_ca_system_score_gemma":0.0009633532,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007091829,"about_ca_topic_score_gemma":0.001611583,"domain_scores_codex":[0.9993394,0.0003898284,0.00002745304,0.0001043741,0.00004291056,0.00009605695],"domain_scores_gemma":[0.9989781,0.0003371625,0.0001951616,0.00008698743,0.00003981611,0.0003627707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9806631,0.003770045,0.0006735985,0.0001791036,0.0003697191,0.00002758768,0.00005538426,0.0003106173,0.00253304,0.00006034163,0.0003911775,0.0109662],"study_design_scores_gemma":[0.875684,0.1199451,0.002348685,0.0000184444,0.0003468345,0.00005716455,0.00003092004,0.0003720478,0.0004540383,0.0001864646,0.0005392975,0.000017003],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950448,0.001832439,0.0002065504,0.000617025,0.000204571,0.000618451,0.0004117519,0.00004004815,0.001024329],"genre_scores_gemma":[0.9911761,0.001587286,0.0006657872,0.0008947636,0.0003255791,0.001336625,0.001083626,0.00002379462,0.002906492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005738767,"threshold_uncertainty_score":0.01919806,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1974685860","doi":"10.5858/arpa.2013-0953-sa","title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update","year":2013,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1793,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Ontario Institute for Cancer Research","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Clinical Oncology; Guideline; Human Epidermal Growth Factor Receptor 2; Medicine; Breast cancer; Clinical Practice; Oncology; Internal medicine; Cancer; Gynecology; Pathology; Family medicine","authors":[{"name":"Antonio C. Wolff","is_ca":false},{"name":"M. Elizabeth Hammond","is_ca":false},{"name":"David G. Hicks","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"Lisa M. McShane","is_ca":false},{"name":"Kimberly H. Allison","is_ca":false},{"name":"D. Craig Allred","is_ca":false},{"name":"John M.S. Bartlett","is_ca":true},{"name":"Michael Bilous","is_ca":false},{"name":"Patrick L. Fitzgibbons","is_ca":false},{"name":"Wedad Hanna","is_ca":true},{"name":"Robert B. Jenkins","is_ca":false},{"name":"Pamela B. Mangu","is_ca":false},{"name":"Soonmyung Paik","is_ca":false},{"name":"Edith A. Perez","is_ca":false},{"name":"Michael F. Press","is_ca":false},{"name":"Patricia A. Spears","is_ca":false},{"name":"Gail H. Vance","is_ca":false},{"name":"Giuseppe Viale","is_ca":false},{"name":"Daniel F. Hayes","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1532947712403345,"gpt":0.5152501178346831,"spread":0.3619553465943486,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01617794,0.001307282,0.00219036,0.007355032,0.001256811,0.00294693,0.005365675,0.008037216,0.00864321],"category_scores_gemma":[0.05418366,0.0009883808,0.004075865,0.005988037,0.001069169,0.003019148,0.002542207,0.007812317,0.008173699],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004510709,"about_ca_system_score_gemma":0.02175514,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02407807,"about_ca_topic_score_gemma":0.04249894,"domain_scores_codex":[0.98036,0.007558757,0.004732918,0.0006337165,0.006039177,0.0006754574],"domain_scores_gemma":[0.9310493,0.01203747,0.006412728,0.001204833,0.0472587,0.002037002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000394685,0.0001626432,0.001215771,0.003579179,0.00007451632,0.0003152649,0.000216752,0.0004296876,0.0002964507,0.001722632,0.8246461,0.1673016],"study_design_scores_gemma":[0.0002680123,0.0001035349,0.004580072,0.03078511,0.0003619407,0.001420836,0.0003353257,0.0006742695,0.0003395779,0.004134624,0.9568987,0.00009788539],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.004028302,0.2081528,0.02712314,0.5902852,0.02334121,0.01085694,0.01583802,0.001609104,0.1187653],"genre_scores_gemma":[0.02100548,0.3475247,0.2261121,0.2846223,0.01016017,0.01824526,0.05271911,0.0006682007,0.03894269],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.02407807,"threshold_uncertainty_score":0.08555812,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3156985612","doi":"10.1056/nejmoa2028485","title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","year":2021,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1543,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Vinorelbine; Metastatic breast cancer; Oncology; Breast cancer; Chemotherapy; Eribulin; Gemcitabine; Cancer; Gastroenterology; Surgery; Confidence interval","authors":[{"name":"Aditya Bardia","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false},{"name":"Delphine Loirat","is_ca":false},{"name":"Kevin Punie","is_ca":false},{"name":"Mafalda Oliveira","is_ca":false},{"name":"Adam Brufsky","is_ca":false},{"name":"Sagar Sardesai","is_ca":false},{"name":"Kevin Kalinsky","is_ca":false},{"name":"Amelia Zelnak","is_ca":false},{"name":"Robert Weaver","is_ca":false},{"name":"Tiffany A. Traina","is_ca":false},{"name":"Florence Dalenc","is_ca":false},{"name":"Philippe Aftimos","is_ca":false},{"name":"Filipa Lynce","is_ca":false},{"name":"Sami Diab","is_ca":false},{"name":"Javier Cortés","is_ca":false},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Cristiano Ferrario","is_ca":true},{"name":"Peter Schmid","is_ca":false},{"name":"Lisa A. Carey","is_ca":false},{"name":"Luca Gianni","is_ca":false},{"name":"Martine Piccart","is_ca":false},{"name":"Sibylle Loibl","is_ca":false},{"name":"David M. Goldenberg","is_ca":false},{"name":"Quan Hong","is_ca":false},{"name":"Martin Olivo","is_ca":false},{"name":"Loretta M. Itri","is_ca":false},{"name":"Hope S. Rugo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05153200415118789,"gpt":0.3885479570907073,"spread":0.3370159529395194,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005771544,0.0002701707,0.0007610483,0.0001696448,0.0001244486,0.0002875465,0.0002240305,0.0002699289,0.00136499],"category_scores_gemma":[0.0006253499,0.0001025921,0.0003163184,0.0001888751,0.0002640497,0.0001629209,0.0001548583,0.0004387301,0.0001232622],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004572098,"about_ca_system_score_gemma":0.0005924434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007456594,"about_ca_topic_score_gemma":0.002175403,"domain_scores_codex":[0.9998558,0.00006631629,0.00001308374,0.00001837132,0.00002667409,0.00001977345],"domain_scores_gemma":[0.9997497,0.00007832888,0.00006845062,0.000008213357,0.00001517115,0.00008023054],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6007553,0.005448997,0.03410167,0.003073925,0.001515691,0.0008189066,0.00027868,0.004273102,0.04079322,0.0006077912,0.002142829,0.3061898],"study_design_scores_gemma":[0.3184512,0.5222692,0.1089164,0.0006094365,0.003393793,0.005014874,0.0003103571,0.006539036,0.01945277,0.001224683,0.01377173,0.00004649652],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922156,0.006568769,0.00008331595,0.0001430003,0.00003314469,0.0001439134,0.00004911232,0.00001026096,0.0007528157],"genre_scores_gemma":[0.9967205,0.002522685,0.0001758857,0.00009586846,0.00003623264,0.00008534991,0.00009470784,0.000001593701,0.0002672612],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00136499,"threshold_uncertainty_score":0.004566312,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2045324973","doi":"10.1016/s0140-6736(07)60028-2","title":"2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial","year":2007,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1511,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Institute of Cancer Research","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Hazard ratio; Breast cancer; Oncology; Clinical endpoint; Clinical trial; Chemotherapy; Adjuvant; Cancer; Surgery; Confidence interval","authors":[{"name":"Ian Smith","is_ca":true},{"name":"Marion Procter","is_ca":false},{"name":"Richard D. Gelber","is_ca":false},{"name":"Sébastien Guillaume","is_ca":false},{"name":"A. Feyereislova","is_ca":false},{"name":"Mitch Dowsett","is_ca":true},{"name":"Aron Goldhirsch","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Gabriella Mariani","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Manfred Kaufmann","is_ca":false},{"name":"David Cameron","is_ca":false},{"name":"Richard H. Bell","is_ca":false},{"name":"Jonas Bergh","is_ca":false},{"name":"Robert L. Coleman","is_ca":false},{"name":"Andrew Wardley","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"R.I. Lopez","is_ca":false},{"name":"Peter Mallmann","is_ca":false},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Nicholas Wilcken","is_ca":false},{"name":"Erik Wist","is_ca":false},{"name":"Pedro Sánchez‐Rovira","is_ca":false},{"name":"Martine Piccart","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02317066928127298,"gpt":0.3436008290136301,"spread":0.3204301597323572,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00456464,0.003051752,0.007672349,0.0006691964,0.0008425119,0.002174023,0.001865036,0.005768951,0.009408829],"category_scores_gemma":[0.006243457,0.001608285,0.005529016,0.0009433581,0.002274588,0.00255973,0.001109112,0.006683202,0.001446211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001866025,"about_ca_system_score_gemma":0.001675513,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003384917,"about_ca_topic_score_gemma":0.00354606,"domain_scores_codex":[0.9968643,0.001672205,0.0002173343,0.0005664721,0.0001742994,0.0005053386],"domain_scores_gemma":[0.9965045,0.001432048,0.0007496455,0.0004191484,0.0002081166,0.0006864309],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9963177,0.0006488695,0.0002109303,0.0002708132,0.0008184753,0.00001969163,0.00001759883,0.00008618982,0.0001920436,0.00003269824,0.0001455711,0.001239384],"study_design_scores_gemma":[0.9807087,0.01593056,0.001122155,0.00005763672,0.0014696,0.00001630245,0.00001811704,0.0001930418,0.0000847381,0.00012811,0.0002548701,0.00001612175],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9653976,0.01902366,0.001247847,0.001980045,0.004116011,0.003852542,0.001503649,0.0001810966,0.002697595],"genre_scores_gemma":[0.9830387,0.004301418,0.0009142993,0.001494603,0.001298882,0.003722663,0.001128432,0.00003148272,0.00406957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009408829,"threshold_uncertainty_score":0.03147566,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2995808512","doi":"10.1056/nejmoa1914609","title":"Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1313,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Seattle Genetics","keywords":"Capecitabine; Trastuzumab; Metastatic breast cancer; Oncology; Medicine; Internal medicine; Breast cancer; Cancer; Colorectal cancer","authors":[{"name":"Rashmi K. Murthy","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Alicia Okines","is_ca":false},{"name":"Elisavet Paplomata","is_ca":false},{"name":"Erika Hamilton","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Nancy U. Lin","is_ca":false},{"name":"Virginia F. Borges","is_ca":false},{"name":"Vandana G. Abramson","is_ca":false},{"name":"Carey K. Anders","is_ca":false},{"name":"Philippe L. Bédard","is_ca":true},{"name":"Mafalda Oliveira","is_ca":false},{"name":"Erik Jakobsen","is_ca":false},{"name":"Thomas Bachelot","is_ca":false},{"name":"Shlomit Strulov Shachar","is_ca":false},{"name":"Volkmar Müller","is_ca":false},{"name":"Sofía Braga","is_ca":false},{"name":"François P. Duhoux","is_ca":false},{"name":"Richard Greil","is_ca":false},{"name":"David Cameron","is_ca":false},{"name":"Lisa A. Carey","is_ca":false},{"name":"Giuseppe Curigliano","is_ca":false},{"name":"Karen A. Gelmon","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false},{"name":"Ian E. Krop","is_ca":false},{"name":"Sibylle Loibl","is_ca":false},{"name":"Mark D. Pegram","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false},{"name":"Maria Corinna Palanca-Wessels","is_ca":false},{"name":"Luke Walker","is_ca":false},{"name":"Wentao Feng","is_ca":false},{"name":"Eric P. Winer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03135860786207033,"gpt":0.3704714722607771,"spread":0.3391128643987068,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007405127,0.0002854768,0.000698059,0.0002986777,0.000162619,0.0002410457,0.0002230645,0.000413674,0.002366028],"category_scores_gemma":[0.001162027,0.0001025143,0.0003365923,0.000267299,0.0002723314,0.0001608192,0.0001744282,0.0005163798,0.0001970014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004570871,"about_ca_system_score_gemma":0.0005949184,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005207922,"about_ca_topic_score_gemma":0.00166682,"domain_scores_codex":[0.9996208,0.0001932015,0.00003446153,0.00004834149,0.00005970761,0.00004353122],"domain_scores_gemma":[0.9997553,0.00007466535,0.00006965219,0.00001116641,0.00001085881,0.00007844071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3538754,0.007371324,0.0171454,0.002709212,0.001563231,0.0007596551,0.0001294401,0.004554329,0.01566115,0.00134424,0.00544341,0.5894431],"study_design_scores_gemma":[0.5757533,0.2708189,0.095662,0.0007289834,0.002557074,0.003599963,0.0001253536,0.005217191,0.006283418,0.002293845,0.03688997,0.0000698872],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9728823,0.0211024,0.0004367192,0.0007691212,0.0002112062,0.0009570416,0.0001565227,0.00003194705,0.003452716],"genre_scores_gemma":[0.9924465,0.005068997,0.0004704933,0.0003682342,0.000166119,0.0005445176,0.0001738361,0.000002166016,0.0007592456],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002366028,"threshold_uncertainty_score":0.007915199,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387865238","doi":"10.1200/jco.23.02005","title":"Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":931,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Takeda Oncology; Genentech; Menarini Group; PharmaMar; European Society for Medical Oncology; Eisai; Seagen; Jounce Therapeutics; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; AstraZeneca; Novocure; Eisai Canada; Cholangiocarcinoma Foundation; F. Hoffmann-La Roche; Taiho Pharmaceutical; University of Texas MD Anderson Cancer Center; Puma Biotechnology; Regeneron Pharmaceuticals; European Organisation for Research and Treatment of Cancer; Mersana Therapeutics; Karyopharm Therapeutics; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Internal medicine; Trastuzumab; Immunohistochemistry; Clinical endpoint; Gastroenterology; Oncology; Surgery; Cancer; Breast cancer; Clinical trial","authors":[{"name":"Funda Meric‐Bernstam","is_ca":false},{"name":"Vicky Makker","is_ca":false},{"name":"Ana Oaknin","is_ca":false},{"name":"Do‐Youn Oh","is_ca":false},{"name":"Susana Banerjee","is_ca":false},{"name":"Antonio González-Martı́n","is_ca":false},{"name":"Kyung Hae Jung","is_ca":false},{"name":"Iwona Ługowska","is_ca":false},{"name":"Luís Manso","is_ca":false},{"name":"Aránzazu Manzano","is_ca":false},{"name":"Bohuslav Melichar","is_ca":false},{"name":"Salvatore Siena","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Anitra Fielding","is_ca":false},{"name":"Yan Ma","is_ca":false},{"name":"Soham D. Puvvada","is_ca":false},{"name":"Norah J. Shire","is_ca":false},{"name":"Jung‐Yun Lee","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.161277714946747,"gpt":0.5034432526818972,"spread":0.3421655377351502,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001753727,0.0007219521,0.001048108,0.0001923382,0.0002082547,0.0007142502,0.0003011519,0.0004724509,0.001331609],"category_scores_gemma":[0.0009854683,0.0001985958,0.0008045186,0.000229382,0.0004040637,0.0004321389,0.0002087087,0.001243649,0.0002627854],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007933261,"about_ca_system_score_gemma":0.0006857576,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005699217,"about_ca_topic_score_gemma":0.001412263,"domain_scores_codex":[0.9996344,0.0001918287,0.00002615789,0.00004969072,0.00004690533,0.00005093066],"domain_scores_gemma":[0.9993641,0.0001542992,0.0001861008,0.00003419631,0.00004058596,0.000220743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7206991,0.01691626,0.06368087,0.0008715129,0.003111296,0.0004351881,0.0003470696,0.004293877,0.01873009,0.0002279227,0.007141156,0.1635456],"study_design_scores_gemma":[0.5305281,0.2918528,0.1554397,0.0001533074,0.002070789,0.001327893,0.0001391369,0.004300943,0.006132687,0.0003758319,0.007628632,0.00005017705],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957266,0.002362277,0.0001447085,0.0001997704,0.00002827336,0.0002061637,0.0004508233,0.00002083636,0.0008605513],"genre_scores_gemma":[0.9960141,0.0009512624,0.0002447498,0.0002861237,0.00006782632,0.0001650526,0.001607505,0.000007601097,0.0006558032],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001753727,"threshold_uncertainty_score":0.009274721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2098544382","doi":"10.1093/jnci/93.24.1852","title":"Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)","year":2001,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":889,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Trastuzumab; SKBR3; Cell growth; Cancer research; Growth inhibition; Insulin-like growth factor; Receptor; Growth factor; Growth factor receptor; Biology; Endocrinology; Internal medicine; Chemistry; Cancer cell; Breast cancer; Medicine; Cancer; Biochemistry","authors":[{"name":"Yen‐Yu Lu","is_ca":true},{"name":"Xiaolin Zi","is_ca":false},{"name":"Yuqing Zhao","is_ca":false},{"name":"Desmond Mascarenhas","is_ca":false},{"name":"Michaël Pollak","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09529036687241335,"gpt":0.3876312492150588,"spread":0.2923408823426454,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003428249,0.0003036014,0.0002395589,0.0001804676,0.00007208965,0.0003134906,0.000195866,0.0003817031,0.001702069],"category_scores_gemma":[0.0004131963,0.0001132845,0.0001826217,0.0002387936,0.0002128672,0.0001619536,0.000124275,0.0004661659,0.0003304055],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003680175,"about_ca_system_score_gemma":0.0001364273,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003627358,"about_ca_topic_score_gemma":0.0002029202,"domain_scores_codex":[0.9998446,0.00003335481,0.0000144144,0.00003424454,0.00003834841,0.00003501753],"domain_scores_gemma":[0.9997976,0.00004571482,0.00009809328,0.000009649621,0.00001727191,0.00003161648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004448667,0.0006450502,0.07420441,0.0005697167,0.0001848517,0.003031934,0.0001229543,0.0006935277,0.8341857,0.0007806839,0.002903876,0.07822859],"study_design_scores_gemma":[0.0008692359,0.008984662,0.3816094,0.0001541457,0.0004636855,0.0521029,0.000214698,0.004328819,0.5066035,0.001050178,0.04357514,0.00004362316],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9669566,0.02604662,0.001281755,0.0006327011,0.00007962648,0.00005351337,0.0002171088,0.00008272638,0.004649463],"genre_scores_gemma":[0.9923853,0.004901843,0.0006115899,0.0002015556,0.00005040764,0.00002535615,0.0002716625,0.000007699302,0.001544668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001702069,"threshold_uncertainty_score":0.005693972,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2379981061","doi":"10.1016/s1470-2045(16)00163-7","title":"5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":874,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hôpital du Saint-Sacrement","funders":"European Society for Medical Oncology","keywords":"Pertuzumab; Docetaxel; Medicine; Trastuzumab; Clinical endpoint; Epirubicin; Internal medicine; Breast cancer; Oncology; Neoadjuvant therapy; Surgery; Cancer; Clinical trial","authors":[{"name":"Luca Gianni","is_ca":false},{"name":"Tadeusz Pieńkowski","is_ca":false},{"name":"Young‐Hyuck Im","is_ca":false},{"name":"Ling‐Ming Tseng","is_ca":false},{"name":"Mei-Ching Liu","is_ca":false},{"name":"Aňa Lluch","is_ca":false},{"name":"Elżbieta Starosławska","is_ca":false},{"name":"Juan de la Haba-Rodríguez","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"José Luiz Pedrini","is_ca":false},{"name":"Brigitte Poirier","is_ca":true},{"name":"Paolo Morandi","is_ca":false},{"name":"Semiglazov Vf","is_ca":false},{"name":"Vichien Srimuninnimit","is_ca":false},{"name":"Giulia Bianchi","is_ca":false},{"name":"Domenico Magazzù","is_ca":false},{"name":"Virginia McNally","is_ca":false},{"name":"Hannah Douthwaite","is_ca":false},{"name":"Graham Ross","is_ca":false},{"name":"Pinuccia Valagussa","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0391025579184239,"gpt":0.3926124320995352,"spread":0.3535098741811113,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003864198,0.002467448,0.00342452,0.0004077828,0.0004240242,0.00173038,0.001131061,0.002241338,0.005341908],"category_scores_gemma":[0.003271073,0.000933811,0.003972881,0.0004707353,0.001572924,0.002107309,0.0007905553,0.004412704,0.001100194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001521389,"about_ca_system_score_gemma":0.001193496,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001339325,"about_ca_topic_score_gemma":0.002689162,"domain_scores_codex":[0.9983248,0.0009992654,0.00007390347,0.0002458246,0.0000915694,0.0002647072],"domain_scores_gemma":[0.9978074,0.0006955063,0.0004732285,0.0002221727,0.0001142158,0.0006875664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9913191,0.001695986,0.0006614439,0.0001732553,0.001079657,0.00002540676,0.00003991152,0.0003226841,0.0008929982,0.00005777186,0.0002849551,0.003446753],"study_design_scores_gemma":[0.9155979,0.07646539,0.004414513,0.00004079149,0.00167816,0.00004913462,0.00005660714,0.0006028629,0.0002545603,0.0002362266,0.0005730079,0.00003092815],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9922221,0.003546895,0.0004663352,0.0007316092,0.0005181865,0.0006323385,0.0006910554,0.00004938129,0.00114205],"genre_scores_gemma":[0.9907951,0.001767138,0.000780492,0.000913752,0.0004957704,0.0009425954,0.001574127,0.00003108838,0.002699999],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005341908,"threshold_uncertainty_score":0.02043611,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2140055441","doi":"10.1200/jco.2008.20.6847","title":"Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"F. Hoffmann-La Roche; Sanofi; AstraZeneca; Eli Lilly and Company","keywords":"Anastrozole; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Hazard ratio; Oncology; Breast cancer; Aromatase inhibitor; Gynecology; Cancer; Tamoxifen; Confidence interval","authors":[{"name":"Bella Kaufman","is_ca":true},{"name":"John R. Mackey","is_ca":true},{"name":"Michael Clemens","is_ca":true},{"name":"P. P. Bapsy","is_ca":true},{"name":"Ashok K. Vaid","is_ca":true},{"name":"Andrew Wardley","is_ca":true},{"name":"Sergei Tjulandin","is_ca":true},{"name":"Michaela K. Jahn","is_ca":true},{"name":"Michaela Lehle","is_ca":true},{"name":"A. Feyereislova","is_ca":true},{"name":"Cédric Révil","is_ca":true},{"name":"Alison Jones","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1158062761522462,"gpt":0.47668609962928,"spread":0.3608798234770338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001839366,0.001006453,0.00200939,0.0003585457,0.0002018225,0.00074298,0.0005698139,0.0009476272,0.002567432],"category_scores_gemma":[0.001622093,0.0004503379,0.001611602,0.0003255128,0.0006189022,0.0007335606,0.0002727703,0.001845297,0.0004412104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006921702,"about_ca_system_score_gemma":0.0009386999,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006622195,"about_ca_topic_score_gemma":0.002029365,"domain_scores_codex":[0.9994779,0.0003343206,0.00003107004,0.00005809145,0.00004588384,0.00005274171],"domain_scores_gemma":[0.9992142,0.0002463197,0.0002099415,0.00004853672,0.00003912485,0.0002418729],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.969017,0.004692823,0.0009208847,0.0002287074,0.001079794,0.00002312788,0.0000342502,0.0004485411,0.003058401,0.00005312813,0.0006395527,0.01980367],"study_design_scores_gemma":[0.8267493,0.1651165,0.004232074,0.00003946403,0.00133499,0.00005927298,0.00002533146,0.0007587024,0.0007684006,0.000160756,0.0007412158,0.00001396309],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926042,0.004361263,0.0002917815,0.0004619126,0.0002773188,0.0006853466,0.0004237318,0.00004437041,0.0008500769],"genre_scores_gemma":[0.992008,0.002976312,0.0008936708,0.0007247285,0.0003952459,0.0008696443,0.0007243585,0.00001497979,0.001393182],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002567432,"threshold_uncertainty_score":0.009727657,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2982411421","doi":"10.1158/1541-7786.mcr-19-0582","title":"Antibody–Drug Conjugates: A Comprehensive Review","year":2019,"lang":"en","type":"review","venue":"Molecular Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":770,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Sherbrooke","funders":"Natural Science Foundation of Jiangsu Province; National Natural Science Foundation of China","keywords":"Antibody-drug conjugate; Drug; Payload (computing); Monoclonal antibody; Cytotoxic T cell; Immunotherapy; Computational biology; Cancer immunotherapy; Cancer research; Medicine; Pharmacology; Cancer; Antibody; Chemistry; Biology; Computer science; Immunology; In vitro; Biochemistry; Internal medicine","authors":[{"name":"Puregmaa Khongorzul","is_ca":false},{"name":"Cai Ling","is_ca":false},{"name":"Farhan Ullah Khan","is_ca":false},{"name":"Awais Ullah Ihsan","is_ca":true},{"name":"Juan Zhang","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.354517806902707,"gpt":0.6034749384917816,"spread":0.2489571315890746,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000449406,0.0009840383,0.001089662,0.002357547,0.0002492551,0.0008873161,0.0006919525,0.0008566852,0.007332601],"category_scores_gemma":[0.0005731789,0.0003196174,0.0005239042,0.002352698,0.000249372,0.001155252,0.0005728389,0.001345271,0.003735789],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004925667,"about_ca_system_score_gemma":0.001029406,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007810925,"about_ca_topic_score_gemma":0.00151575,"domain_scores_codex":[0.9998254,0.0000269806,0.00002445564,0.00003072079,0.00007384211,0.00001860313],"domain_scores_gemma":[0.9997914,0.00009473979,0.00003212011,0.000007609097,0.00005580396,0.00001837836],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005759953,0.0001126576,0.0001040422,0.02235985,0.00007522252,0.0001555167,0.00004800753,0.0004270131,0.002501348,0.003717695,0.04352245,0.9269187],"study_design_scores_gemma":[0.000009473484,0.00006661639,0.0001985735,0.002005375,0.00005495084,0.0004726702,0.00001592671,0.00005551895,0.0004044742,0.0006198236,0.9960872,0.000009440728],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001888754,0.9968437,0.000195935,0.0001926981,0.0002850868,0.00001250586,0.00004675806,0.00001511657,0.002219347],"genre_scores_gemma":[0.0006997648,0.9974602,0.000300277,0.0001723945,0.0001347413,0.00001283032,0.00006675817,0.000002467212,0.001150448],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.007332601,"threshold_uncertainty_score":0.02452999,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2616596696","doi":"10.1016/s1470-2045(17)30312-1","title":"Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":656,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Genentech; GlaxoSmithKline","keywords":"Medicine; Lapatinib; Capecitabine; Trastuzumab emtansine; Taxane; Trastuzumab; Internal medicine; Oncology; Breast cancer; Interim analysis; Metastatic breast cancer; Pertuzumab; Population; Cancer; Clinical trial; Colorectal cancer","authors":[{"name":"Véronique Dièras","is_ca":false},{"name":"David Miles","is_ca":false},{"name":"Sunil Verma","is_ca":true},{"name":"Mark D. Pegram","is_ca":false},{"name":"Manfred Welslau","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Ian E. Krop","is_ca":false},{"name":"Kim T. Blackwell","is_ca":false},{"name":"Silke Hoersch","is_ca":false},{"name":"Jin Xu","is_ca":false},{"name":"Marjorie Green","is_ca":false},{"name":"Luca Gianni","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1471450445887598,"gpt":0.4395473762209945,"spread":0.2924023316322347,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004610684,0.001267118,0.002465228,0.0005863075,0.0002453,0.000966606,0.0006505223,0.001035594,0.003281882],"category_scores_gemma":[0.004557875,0.0004718846,0.003599701,0.0005857389,0.0008437314,0.001303961,0.0004604259,0.002068508,0.0004045939],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001062009,"about_ca_system_score_gemma":0.0005846418,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005156995,"about_ca_topic_score_gemma":0.00171987,"domain_scores_codex":[0.9977018,0.001572963,0.0001561477,0.0002551998,0.0001181151,0.0001957784],"domain_scores_gemma":[0.9970365,0.001680623,0.000721331,0.0001954867,0.0000796403,0.0002864994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9762517,0.001541024,0.002200026,0.0004498552,0.003045188,0.00003522774,0.00006083401,0.0005912848,0.001098493,0.00005551014,0.000293942,0.01437683],"study_design_scores_gemma":[0.8068581,0.1589113,0.02463636,0.0001409268,0.005647557,0.0001451757,0.00009211671,0.001322762,0.0007014854,0.0003490678,0.001142163,0.00005291372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990703,0.006063764,0.0003509795,0.0002435071,0.0001497291,0.0007176925,0.0007722963,0.00003117355,0.0009678557],"genre_scores_gemma":[0.9945132,0.0017416,0.0005507201,0.0004577847,0.00017701,0.0005268799,0.001131916,0.00001347419,0.0008875315],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004610684,"threshold_uncertainty_score":0.02438396,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2101299592","doi":"10.1200/jco.2009.24.2024","title":"Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy","year":2010,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":640,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"American Society of Clinical Oncology","keywords":"Pertuzumab; Trastuzumab; Medicine; Metastatic breast cancer; Internal medicine; Oncology; Adverse effect; Breast cancer; Cancer; Clinical trial; Phases of clinical research; Loading dose","authors":[{"name":"José Baselga","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Shailendra Verma","is_ca":true},{"name":"Andrew Wardley","is_ca":true},{"name":"PierFranco Conte","is_ca":true},{"name":"David Miles","is_ca":true},{"name":"Giulia Bianchi","is_ca":true},{"name":"Javier Cortés","is_ca":true},{"name":"Virginia McNally","is_ca":true},{"name":"Graham Ross","is_ca":true},{"name":"P. Fumoleau","is_ca":true},{"name":"Luca Gianni","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1176703880999536,"gpt":0.4940915774878471,"spread":0.3764211893878935,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001833406,0.002031585,0.002203474,0.0004491412,0.0004045715,0.0009459917,0.0008882415,0.001490613,0.00300769],"category_scores_gemma":[0.001449786,0.0006828945,0.001182155,0.0004216643,0.001068786,0.0008702534,0.0004351072,0.002585803,0.0006822603],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009642903,"about_ca_system_score_gemma":0.001770868,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008363509,"about_ca_topic_score_gemma":0.001313088,"domain_scores_codex":[0.9993185,0.0003950638,0.00003380736,0.00008045247,0.00005540455,0.0001167947],"domain_scores_gemma":[0.9990004,0.0001737537,0.0001721592,0.00006527953,0.00005320887,0.0005351852],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8822356,0.04273253,0.00639107,0.0003583848,0.00095717,0.0003766601,0.0002743307,0.002052594,0.0159623,0.0002401769,0.002109523,0.04630964],"study_design_scores_gemma":[0.7327421,0.2571223,0.005967911,0.00001743377,0.0001884693,0.0002088437,0.00003142519,0.001077133,0.001218969,0.00008532775,0.001324144,0.00001587918],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945775,0.001318417,0.0003202251,0.0004152946,0.0001346672,0.00160404,0.0003197512,0.00006175071,0.0012482],"genre_scores_gemma":[0.9903193,0.000974109,0.001110808,0.0007543782,0.0003713064,0.002722038,0.001805185,0.0000192356,0.001923706],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00300769,"threshold_uncertainty_score":0.01006168,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2125620887","doi":"10.1016/s1470-2045(11)70033-x","title":"Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial","year":2011,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":611,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Medicine; Internal medicine; Interim analysis; Breast cancer; Oncology; Clinical endpoint; Population; Adjuvant; Surgery; Clinical trial; Hazard ratio; Cancer; Confidence interval","authors":[{"name":"Luca Gianni","is_ca":false},{"name":"Urania Dafni","is_ca":false},{"name":"Richard D. Gelber","is_ca":false},{"name":"Evandro de Azambuja","is_ca":false},{"name":"Susanne Muehlbauer","is_ca":false},{"name":"Aron Goldhirsch","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Ian Smith","is_ca":false},{"name":"José Baselga","is_ca":false},{"name":"Christian Jackisch","is_ca":false},{"name":"David Cameron","is_ca":false},{"name":"Max S. Mano","is_ca":false},{"name":"José Luiz Pedrini","is_ca":false},{"name":"Andrea Veronesi","is_ca":false},{"name":"César Mendiola","is_ca":false},{"name":"A Płużańska","is_ca":false},{"name":"Semiglazov Vf","is_ca":false},{"name":"Eduard Vrdoljak","is_ca":false},{"name":"Michael J. Eckart","is_ca":false},{"name":"Zhenzhou Shen","is_ca":false},{"name":"George Skiadopoulos","is_ca":false},{"name":"Marion Procter","is_ca":false},{"name":"Kathleen I. Pritchard","is_ca":true},{"name":"Martine Piccart","is_ca":false},{"name":"Richard H. Bell","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0317431920055709,"gpt":0.327746268557953,"spread":0.2960030765523821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004106796,0.002524831,0.006905101,0.0006524436,0.0008286664,0.001964919,0.001606198,0.004299411,0.00563084],"category_scores_gemma":[0.00520819,0.001226116,0.006060629,0.0009387553,0.002016777,0.002383214,0.0008949673,0.005769826,0.0009304335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001869065,"about_ca_system_score_gemma":0.001623591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003359125,"about_ca_topic_score_gemma":0.003949807,"domain_scores_codex":[0.9973013,0.001415005,0.0001905354,0.0004354574,0.0001502246,0.000507383],"domain_scores_gemma":[0.9969304,0.001033168,0.0008012664,0.0003707326,0.0002087652,0.0006556513],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9939172,0.001214197,0.000477851,0.0002282359,0.001069727,0.00002113695,0.00002791905,0.0001164492,0.0002782473,0.00002247117,0.0001662266,0.00246045],"study_design_scores_gemma":[0.9484632,0.04538711,0.003338135,0.0000619971,0.001906469,0.00002242846,0.00003222272,0.0002081039,0.0001377997,0.0001067337,0.0003143454,0.00002136817],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9825045,0.01084186,0.0005645985,0.0009606966,0.00133645,0.00169001,0.000851227,0.00007874102,0.00117185],"genre_scores_gemma":[0.9891058,0.003408131,0.0005484837,0.000983514,0.0006963568,0.001664515,0.00106648,0.00001954929,0.002507136],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006905101,"threshold_uncertainty_score":0.02171904,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2015918488","doi":"10.1038/modpathol.2011.198","title":"HER2 testing in gastric cancer: a practical approach","year":2012,"lang":"en","type":"article","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":596,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Trastuzumab; Immunohistochemistry; Cancer; Breast cancer; Medicine; Fluorescence in situ hybridization; Pathology; Capecitabine; Oncology; CISH; In situ hybridization; Stomach cancer; Adenocarcinoma; Metastatic breast cancer; Companion diagnostic; Internal medicine; Biology; Colorectal cancer","authors":[{"name":"Josef Rüschoff","is_ca":false},{"name":"Wedad Hanna","is_ca":true},{"name":"Michael Bilous","is_ca":false},{"name":"Manfred Hofmann","is_ca":false},{"name":"R. Yoshiyuki Osamura","is_ca":false},{"name":"Frédérique Penault‐Llorca","is_ca":false},{"name":"Marc J. van de Vijver","is_ca":false},{"name":"Giuseppe Viale","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2028628030829037,"gpt":0.4404619443020513,"spread":0.2375991412191476,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009706363,0.001897181,0.001934965,0.004552717,0.001578895,0.005199819,0.004295495,0.007306153,0.007631874],"category_scores_gemma":[0.01373758,0.001103058,0.001375823,0.001068835,0.004396329,0.007911969,0.004420703,0.008933453,0.002844921],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00203646,"about_ca_system_score_gemma":0.002412365,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001277947,"about_ca_topic_score_gemma":0.002234344,"domain_scores_codex":[0.9966485,0.001465515,0.0004009501,0.0003624244,0.0009275916,0.0001950526],"domain_scores_gemma":[0.9924759,0.00409334,0.0002409269,0.0005803767,0.00190785,0.0007015747],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001031165,0.001181341,0.04235137,0.00147234,0.0003036105,0.02891732,0.000926472,0.003867033,0.01078232,0.05371863,0.1118033,0.7436451],"study_design_scores_gemma":[0.0008922186,0.001754825,0.03673914,0.005233079,0.001036499,0.1259366,0.008113743,0.03199309,0.009722082,0.510915,0.2671247,0.0005389084],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"methods","genre_scores_codex":[0.03005529,0.111071,0.4095753,0.3669368,0.00834401,0.0008610864,0.0004278055,0.00164412,0.0710846],"genre_scores_gemma":[0.4208995,0.09478989,0.3661453,0.06267371,0.03795175,0.0009295467,0.0005412481,0.0004092387,0.01565975],"genre_candidate":"methods","genre_consensus":"methods","teacher_disagreement_score":0.009706363,"threshold_uncertainty_score":0.05133277,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2768980003","doi":"10.1016/s1470-2045(17)30717-9","title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":589,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; BC Cancer Agency","funders":"National Institute for Health and Care Research; Puma Biotechnology","keywords":"Medicine; Neratinib; Trastuzumab; Internal medicine; Breast cancer; Oncology; Clinical endpoint; Placebo; Regimen; Metastatic breast cancer; Adverse effect; Cancer; Clinical trial; Pathology","authors":[{"name":"Miguel Martín","is_ca":false},{"name":"Frankie A. Holmes","is_ca":false},{"name":"Bent Ejlertsen","is_ca":false},{"name":"Suzette Delaloge","is_ca":false},{"name":"Beverly Moy","is_ca":false},{"name":"Hiroji Iwata","is_ca":false},{"name":"Gϋnter von Minckwitz","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Janine Mansi","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Michael Gnant","is_ca":false},{"name":"Z. Tomasevic","is_ca":false},{"name":"Neelima Denduluri","is_ca":false},{"name":"Robert Šeparović","is_ca":false},{"name":"Erhan Gökmen","is_ca":false},{"name":"Anna Bashford","is_ca":false},{"name":"Manuel Ruíz Borrego","is_ca":false},{"name":"Sung‐Bae Kim","is_ca":false},{"name":"Erik Jakobsen","is_ca":false},{"name":"A. Ciceniene","is_ca":false},{"name":"Kenichi Inoue","is_ca":false},{"name":"Friedrich Overkamp","is_ca":false},{"name":"Joan B. Heijns","is_ca":false},{"name":"Anne Armstrong","is_ca":false},{"name":"John S. Link","is_ca":false},{"name":"Anil A. Joy","is_ca":true},{"name":"Richard Bryce","is_ca":false},{"name":"Alvin Wong","is_ca":false},{"name":"Susan Moran","is_ca":false},{"name":"Bin Yao","is_ca":false},{"name":"Feng Xu","is_ca":false},{"name":"Alan Auerbach","is_ca":false},{"name":"Marc Buyse","is_ca":false},{"name":"Arlene Chan","is_ca":false},{"name":"Vernon Harvey","is_ca":false},{"name":"Rudolf Tomek","is_ca":false},{"name":"Nicholas J. Robert","is_ca":false},{"name":"Ira Gore","is_ca":false},{"name":"John W. Smith","is_ca":false},{"name":"Norikazu Masuda","is_ca":false},{"name":"S. Di Sean Kendall","is_ca":false},{"name":"William Graydon Harker","is_ca":false},{"name":"Katarína Petráková","is_ca":false},{"name":"Ángel Guerrero‐Zotano","is_ca":false},{"name":"Amparo Ruiz Simón","is_ca":false},{"name":"Zora Neskovic Konstantinovic","is_ca":false},{"name":"Nicholas Iannotti","is_ca":false},{"name":"Pierfrancesco Tassone","is_ca":false},{"name":"Gladys Rodriguez","is_ca":false},{"name":"Noelia Jáñez Martínez","is_ca":false},{"name":"Carmen Crespo Massieu","is_ca":false},{"name":"Snezana Smickoska","is_ca":false},{"name":"Işıl Somali","is_ca":false},{"name":"Uğur Yılmaz","is_ca":false},{"name":"Mirta Garcia Alonso","is_ca":false},{"name":"Adolfo Rosales","is_ca":false},{"name":"Soeren Cold","is_ca":false},{"name":"Ann Knoop","is_ca":false},{"name":"Debra A. Patt","is_ca":false},{"name":"Beth A. Hellerstedt","is_ca":false},{"name":"Ingrid A. Mayer","is_ca":false},{"name":"Julie A. Means‐Powell","is_ca":false},{"name":"Rina Hui","is_ca":false},{"name":"Francis M. Senecal","is_ca":false},{"name":"Richard Hendry De Boer","is_ca":false},{"name":"Zhenzhou Shen","is_ca":false},{"name":"A.A. Luczak","is_ca":false},{"name":"Joanna W.Y. Chui","is_ca":false},{"name":"Janice Tsang","is_ca":false},{"name":"István Láng","is_ca":false},{"name":"Yoshiaki Rai","is_ca":false},{"name":"Yasuo Hozumi","is_ca":false},{"name":"Albert J. ten Tije","is_ca":false},{"name":"Manish Bhandari","is_ca":false},{"name":"Cynthia R. Osborne","is_ca":false},{"name":"Shoichiro Ohtani","is_ca":false},{"name":"Kenji Higaki","is_ca":false},{"name":"Kenichi Watanabe","is_ca":false},{"name":"Kazunori TAGUCHI","is_ca":false},{"name":"Masato Takahashi","is_ca":false},{"name":"Sladjana Filipovic","is_ca":false},{"name":"Vincent Hansen","is_ca":false},{"name":"Vijayarama Phooshkooru Rao","is_ca":false},{"name":"Manish Gupta","is_ca":false},{"name":"Petar Petrov","is_ca":false},{"name":"Bruno Coudert","is_ca":false},{"name":"Željko Vojnović","is_ca":false},{"name":"Zsofia Polya","is_ca":false},{"name":"Toshiko Miyaki","is_ca":false},{"name":"Naohito Yamamoto","is_ca":false},{"name":"Stephen Brincat","is_ca":true},{"name":"Krzysztof Leśniewski-Kmak","is_ca":false},{"name":"Ewa Chmielowska","is_ca":false},{"name":"Ruemu Birhiray","is_ca":false},{"name":"Marc L. Citron","is_ca":false},{"name":"Steven W. Papish","is_ca":false},{"name":"William L. Berry","is_ca":false},{"name":"Sven Tyge Langkjer","is_ca":false},{"name":"José Á. García-Sáenz","is_ca":false},{"name":"Ana Arance","is_ca":false},{"name":"Noa Efrat","is_ca":false},{"name":"Tomasz Sarosiek","is_ca":false},{"name":"Lukasz Grzeda","is_ca":false},{"name":"Yvonne Manalo","is_ca":false},{"name":"Julie C. Smith","is_ca":false},{"name":"Irfan Vaziri","is_ca":false},{"name":"Tabitha Healey","is_ca":false},{"name":"Yasmin Rahim","is_ca":false},{"name":"Cynthia T. Luk","is_ca":false},{"name":"B. Dingle","is_ca":false},{"name":"Sandra Franco","is_ca":false},{"name":"Peter G. Sørensen","is_ca":false},{"name":"Anjana Anand","is_ca":false},{"name":"Sarah Khan","is_ca":false},{"name":"George Fountzilas","is_ca":false},{"name":"Kenjiro Aogi","is_ca":false},{"name":"Satoru Shimizu","is_ca":false},{"name":"Milada Mikulova","is_ca":false},{"name":"S. Špánik","is_ca":false},{"name":"Robert A. Somer","is_ca":false},{"name":"Patrick J. Flynn","is_ca":false},{"name":"Jermaine Coward","is_ca":false},{"name":"Paul N. Mainwaring","is_ca":false},{"name":"Guy Jérusalem","is_ca":false},{"name":"Carine Segura-Ojezzar","is_ca":false},{"name":"Christelle Lévy","is_ca":false},{"name":"T. Delozier","is_ca":false},{"name":"David Khayat","is_ca":false},{"name":"Robert E. Coleman","is_ca":false},{"name":"Martin Rolles","is_ca":false},{"name":"R. Maisano","is_ca":false},{"name":"Mario Nardi","is_ca":false},{"name":"Yoshinori Ito","is_ca":false},{"name":"Perran Fulden Yumuk","is_ca":false},{"name":"Gül Başaran","is_ca":false},{"name":"Nazım Serdar Turhal","is_ca":false},{"name":"Mary Wilkinson","is_ca":false},{"name":"Nathan B. Green","is_ca":false},{"name":"Algis P. Sidrys","is_ca":false},{"name":"Sigrun Hallmeyer","is_ca":false},{"name":"Douglas J. Testori","is_ca":false},{"name":"Srikala S. Sridhar","is_ca":false},{"name":"José Chang","is_ca":false},{"name":"Qiang Sun","is_ca":false},{"name":"Carlos Jara-Sánchez","is_ca":false},{"name":"Xabier Mielgo-Rubio","is_ca":false},{"name":"María Lomas Garrido","is_ca":false},{"name":"Juan de la Haba-Rodríguez","is_ca":false},{"name":"A. Perelló Martorell","is_ca":false},{"name":"Antoni Mestre","is_ca":false},{"name":"Julio Rifa Ferrer","is_ca":false},{"name":"Sonia Del Barco Berrón","is_ca":false},{"name":"Zsuzsanna Nagy","is_ca":false},{"name":"Maki Tanaka","is_ca":false},{"name":"Young‐Hyuck Im","is_ca":false},{"name":"Robert R. Carroll","is_ca":false},{"name":"Laura C. Dickerson","is_ca":false},{"name":"Joseph R. Mace","is_ca":false},{"name":"Ragene Rivera","is_ca":false},{"name":"Leonard M. Klein","is_ca":false},{"name":"Robert L. Ruxer","is_ca":false},{"name":"Sharon Wilks","is_ca":false},{"name":"Dusan Kotasek","is_ca":false},{"name":"Vasil Popov","is_ca":false},{"name":"V. Taskova","is_ca":false},{"name":"Violetka Marinova-Venkova","is_ca":false},{"name":"Constanta Timcheva","is_ca":false},{"name":"Christine Desbiens","is_ca":false},{"name":"Jean-Pierre M. Ayoub","is_ca":false},{"name":"Debjani Grenier","is_ca":false},{"name":"Norbert Marschner","is_ca":false},{"name":"Hans Tesch","is_ca":false},{"name":"Hans-Joachim Lueck","is_ca":false},{"name":"Jan Janßen","is_ca":false},{"name":"Ingo Schwaner","is_ca":false},{"name":"Stine Wahlstrøm","is_ca":false},{"name":"Eva Brix","is_ca":false},{"name":"Susanne Vallentin","is_ca":false},{"name":"Dan Kristensen","is_ca":false},{"name":"Anna Andreeva","is_ca":false},{"name":"Vesna Glavicic","is_ca":false},{"name":"Isabel Calvo Plaza","is_ca":false},{"name":"A. Antón Torres","is_ca":false},{"name":"Corinne Veyret","is_ca":false},{"name":"Jean‐Pierre Bergerat","is_ca":false},{"name":"Emmanuelle Bourbouloux","is_ca":false},{"name":"Wendy Ann Ella","is_ca":false},{"name":"Hafiz Algurafi","is_ca":false},{"name":"A. Robinson","is_ca":false},{"name":"Seung Jin Kim","is_ca":false},{"name":"Tetsuya Taguchi","is_ca":false},{"name":"Elona Juozaitytė","is_ca":false},{"name":"Stanley Madretsma","is_ca":false},{"name":"Sandra A. Radema","is_ca":false},{"name":"Malgorzata Czerniawska-Meier","is_ca":false},{"name":"Wojciech Rogowski","is_ca":false},{"name":"Mária Wagnerová","is_ca":false},{"name":"Donald Richards","is_ca":false},{"name":"Elizabeth Tan-Chiu","is_ca":false},{"name":"Asskikis Vasileios","is_ca":false},{"name":"Charles Henderson","is_ca":false},{"name":"Viran Holden","is_ca":false},{"name":"Xiaojia Wang","is_ca":false},{"name":"Zhongsheng Tong","is_ca":false},{"name":"Junlan Yang","is_ca":false},{"name":"Manuel González","is_ca":false},{"name":"Mahdi Rezai","is_ca":false},{"name":"John Hackmann","is_ca":false},{"name":"Eduardo Martínez de Dueñas","is_ca":false},{"name":"B. Bermejo De Las Heras","is_ca":false},{"name":"Louis Marie Dourthe","is_ca":false},{"name":"Dorothée Chocteau-Bouju","is_ca":false},{"name":"Philippe Bougnoux","is_ca":false},{"name":"Stylianos Kakolyris","is_ca":false},{"name":"Haralabos P. Kalofonos","is_ca":false},{"name":"D. Pectasidis","is_ca":false},{"name":"Ting Ying Ng","is_ca":false},{"name":"Gábor Pajkos","is_ca":false},{"name":"Eva Ezer Somogyine","is_ca":false},{"name":"Giuseppe Tonini","is_ca":false},{"name":"Dario Giuffrida","is_ca":false},{"name":"Shintaro Takao","is_ca":false},{"name":"Makoto Ishitobi","is_ca":false},{"name":"Hideo Inaji","is_ca":false},{"name":"Yutaka Tokuda","is_ca":false},{"name":"Katarzyna Woźniak","is_ca":false},{"name":"Dan Lungulescu","is_ca":false},{"name":"Yen‐Shen Lu","is_ca":false},{"name":"King‐Jen Chang","is_ca":false},{"name":"Julian B. Hill","is_ca":false},{"name":"C. Croot","is_ca":false},{"name":"A. Dekker","is_ca":false},{"name":"Neil D. Belman","is_ca":false},{"name":"Miguel Á. Conde","is_ca":false},{"name":"Richard A. Michaelson","is_ca":false},{"name":"Kathleen Kemmer","is_ca":false},{"name":"Jane Yuet Ching Hui","is_ca":true},{"name":"Shiuh‐Wen Luoh","is_ca":false},{"name":"Kenneth Nahum","is_ca":false},{"name":"Andrew Greenspan","is_ca":false},{"name":"Joni C. Nichols","is_ca":false},{"name":"Carlos A. Encarnacion","is_ca":false},{"name":"Thomas M.J. Niederman","is_ca":false},{"name":"Theresa M. Lee","is_ca":false},{"name":"R. W. Alexander","is_ca":false},{"name":"Robert Gordon","is_ca":false},{"name":"A Tomová","is_ca":false},{"name":"Daniel Rauch","is_ca":false},{"name":"Răzvan Popescu","is_ca":false},{"name":"Gustavo Adolfo Rojas","is_ca":false},{"name":"J Vaňásek","is_ca":false},{"name":"Tanja Neunhoeffer","is_ca":false},{"name":"Jana Barinoff","is_ca":false},{"name":"Gerd Graffunder","is_ca":false},{"name":"Wolfgang Abenhardt","is_ca":false},{"name":"Peter Bojko","is_ca":false},{"name":"Bernhard Heinrich","is_ca":false},{"name":"Albert von der Assen","is_ca":false},{"name":"Bogovic Jurij Antonovic","is_ca":false},{"name":"Lene Adrian","is_ca":false},{"name":"Manuel Ramos Vázquez","is_ca":false},{"name":"Santiago González Santiago","is_ca":false},{"name":"Véronique Dièras","is_ca":false},{"name":"Jill Mercia Bishop","is_ca":false},{"name":"Timothy Perren","is_ca":false},{"name":"Ioannis Varthalitis","is_ca":false},{"name":"Dimitris Mavroudis","is_ca":false},{"name":"Vassilis Georgoulias","is_ca":false},{"name":"Louis WC Chow","is_ca":false},{"name":"Chung Cheung Thomas Yau","is_ca":false},{"name":"Raymond Liang","is_ca":false},{"name":"Béla Pikó","is_ca":false},{"name":"Agnes Wéber","is_ca":false},{"name":"Bella Kaufman","is_ca":false},{"name":"Karen Drumea","is_ca":false},{"name":"Francesco Nuzzo","is_ca":false},{"name":"A. De Matteis","is_ca":false},{"name":"Giacomo Cartenì","is_ca":false},{"name":"Eriko Tokunaga","is_ca":false},{"name":"M. Ishida","is_ca":false},{"name":"Shinji Ohno","is_ca":false},{"name":"Nobuaki Sato","is_ca":false},{"name":"Katsumasa Kuroi","is_ca":false},{"name":"Reiki Nishimura","is_ca":false},{"name":"Junichiro Watanabe","is_ca":false},{"name":"Yoon Ji Choi","is_ca":false},{"name":"Kyong Hwa Park","is_ca":false},{"name":"Marek Z. Wojtukiewicz","is_ca":false},{"name":"Jacek Jassem","is_ca":false},{"name":"Niklas Loman","is_ca":false},{"name":"Sercan Askoy","is_ca":false},{"name":"M. Kadri Altundağ","is_ca":false},{"name":"Pınar Saip","is_ca":false},{"name":"Muhammad Amjad Ali","is_ca":false},{"name":"James L. Wade","is_ca":false},{"name":"A. Jo Chien","is_ca":false},{"name":"Debra Brandt","is_ca":false},{"name":"Yelena Novik","is_ca":false},{"name":"Chirag Jani","is_ca":false},{"name":"Robert Rice","is_ca":false},{"name":"Yousuf Gaffar","is_ca":false},{"name":"Mark Keaton","is_ca":false},{"name":"Rajesh Bajaj","is_ca":false},{"name":"Gretchen Kimmick","is_ca":false},{"name":"David L. Campbell","is_ca":false},{"name":"Theodore Turnquest","is_ca":false},{"name":"Sideras Lucas","is_ca":false},{"name":"Pierre Dubé","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"J Schilling","is_ca":false},{"name":"Klaus Apel","is_ca":false},{"name":"Peter Michael Vestlev","is_ca":false},{"name":"Brita B. Jensen","is_ca":false},{"name":"Vera Haahr","is_ca":false},{"name":"Álvaro Rodríguez Lescure","is_ca":false},{"name":"C. Saura Manich","is_ca":false},{"name":"Jean-Philippe Jacquin","is_ca":false},{"name":"Ahmed Samreen","is_ca":false},{"name":"Ion Boiangiu","is_ca":false},{"name":"Magdolna Dank","is_ca":false},{"name":"Cristina Falci","is_ca":false},{"name":"Antonio Jirillo","is_ca":false},{"name":"Saverio Cinieri","is_ca":false},{"name":"Takayuki Ueno","is_ca":false},{"name":"Fumiaki Sato","is_ca":false},{"name":"Hiroyasu Yamashiro","is_ca":false},{"name":"Tomoharu Sugie","is_ca":false},{"name":"Keun Seok Lee","is_ca":false},{"name":"Jung Sil Ro","is_ca":false},{"name":"In Hae Park","is_ca":false},{"name":"Anita Zarina Bustam","is_ca":false},{"name":"Małgorzata Suszko-Każarnowicz","is_ca":false},{"name":"A. Piktel","is_ca":false},{"name":"Krzysztof Krzemieniecki","is_ca":false},{"name":"Polizenia Georgeta Iorga","is_ca":false},{"name":"Yoon Sim Yap","is_ca":false},{"name":"M. Kakalejcik","is_ca":false},{"name":"Alper Sevinc","is_ca":false},{"name":"Mustafa Özgüroğlu","is_ca":false},{"name":"Shin‐Cheh Chen","is_ca":false},{"name":"Richard H. Greenberg","is_ca":false},{"name":"Allan Daniel Eisemann","is_ca":false},{"name":"Robert Droder","is_ca":false},{"name":"Mustafa Abbasi","is_ca":false},{"name":"Marina Vaysburd","is_ca":false},{"name":"Humberto Caldera","is_ca":false},{"name":"Barbara Haley","is_ca":false},{"name":"Erwin Robin","is_ca":false},{"name":"Roger Inhorn","is_ca":false},{"name":"David Hufnagel","is_ca":false},{"name":"Peter Kenyon","is_ca":false},{"name":"Ellen N. Spremulli","is_ca":false},{"name":"Paula Silverman","is_ca":false},{"name":"Sharad Jain","is_ca":false},{"name":"Robert T. Weigand","is_ca":false},{"name":"Jeroen Mebis","is_ca":false},{"name":"Tatyana Koynova","is_ca":false},{"name":"Bernard Lespérance","is_ca":false},{"name":"Jana Prausová","is_ca":false},{"name":"Claus‐Henning Köhne","is_ca":false},{"name":"Andreas Schneeweiß","is_ca":false},{"name":"Christian Jackisch","is_ca":false},{"name":"Stefan Fuxius","is_ca":false},{"name":"Ricardo Cubedo Cervera","is_ca":false},{"name":"Ander Urruticoechea Ribate","is_ca":false},{"name":"J. V. Álvarez Gallego","is_ca":false},{"name":"Angels Arcusa Lanza","is_ca":false},{"name":"María del Pilar Álvarez","is_ca":false},{"name":"Jesús Florián Gericó","is_ca":false},{"name":"Laurent Cany","is_ca":false},{"name":"Justin Stebbing","is_ca":false},{"name":"Dejan Labudovic","is_ca":false},{"name":"Damir Gugić","is_ca":false},{"name":"Damir Vrbanec","is_ca":false},{"name":"Fausto Roila","is_ca":false},{"name":"Sandro Barni","is_ca":false},{"name":"Paolo Bidoli","is_ca":false},{"name":"Hirofumi Mukai","is_ca":false},{"name":"Vanessa Bermudez","is_ca":false},{"name":"Alexandru Eniu","is_ca":false},{"name":"B. Mirtsching","is_ca":false},{"name":"Emad Ibrahim","is_ca":false},{"name":"Joan E. Trey","is_ca":false},{"name":"Paul Hergenroeder","is_ca":false},{"name":"Aftab Mahmood","is_ca":false},{"name":"Anneliese Gonzalez","is_ca":false},{"name":"Edward H. Kaplan","is_ca":false},{"name":"Stacy Ban","is_ca":false},{"name":"Dhimant Patel","is_ca":false},{"name":"Billy Clowney","is_ca":false},{"name":"Karen Hoelzer","is_ca":false},{"name":"Garry Schwartz","is_ca":false},{"name":"Mohamed Salkeni","is_ca":false},{"name":"Jame Abraham","is_ca":true},{"name":"Sunil Narula","is_ca":false},{"name":"Khaled W. Jabboury","is_ca":false},{"name":"Robert S. Mocharnuk","is_ca":false},{"name":"Richard H. McDonough","is_ca":false},{"name":"David Sikes","is_ca":false},{"name":"Ronald H. Kawanchi","is_ca":false},{"name":"Larry Schlabach","is_ca":false},{"name":"Samuel S. McCachren","is_ca":false},{"name":"Thomas M. Cosgriff","is_ca":false},{"name":"Luke Dreisbach","is_ca":false},{"name":"Angela DeMichele","is_ca":false},{"name":"L. Pawl","is_ca":false},{"name":"Jennifer Lucas","is_ca":false},{"name":"Lowell C. Shinn","is_ca":false},{"name":"Nabiel Alkhouri","is_ca":false},{"name":"Manish Monga","is_ca":false},{"name":"Deborah Lindquist","is_ca":false},{"name":"T Anderson","is_ca":false},{"name":"Humera Khurshid","is_ca":false},{"name":"Sabrina Witherby","is_ca":false},{"name":"Nicholette Erickson","is_ca":false},{"name":"Ann Traynor","is_ca":false},{"name":"Ron Bose","is_ca":false},{"name":"Timothy Pluard","is_ca":false},{"name":"Michael Jones","is_ca":false},{"name":"Sucharu Prakash","is_ca":false},{"name":"Fabio Volterra","is_ca":false},{"name":"Gerardo Capo","is_ca":false},{"name":"Lawrence E. Flaherty","is_ca":false},{"name":"Elaina M. Gartner","is_ca":false},{"name":"Said Baidas","is_ca":false},{"name":"Ian J. Okazaki","is_ca":false},{"name":"Bichlien Nguyen","is_ca":false},{"name":"Thomas J. Rakowski","is_ca":false},{"name":"Ira A. Oliff","is_ca":false},{"name":"Joseph W. Leach","is_ca":false},{"name":"Daniel M. Anderson","is_ca":false},{"name":"Kendra Kubiak","is_ca":false},{"name":"Michaela L. Tsai","is_ca":false},{"name":"Philippe Vroman","is_ca":false},{"name":"Ines Deleu","is_ca":false},{"name":"Willem Lybaert","is_ca":false},{"name":"Marleen Borms","is_ca":false},{"name":"Félix Couture","is_ca":false},{"name":"Jonathan J. Wilson","is_ca":false},{"name":"Gordon C. Hunt","is_ca":false},{"name":"David R. Holland","is_ca":false},{"name":"Walter Mingrone","is_ca":false},{"name":"Shusen Wang","is_ca":false},{"name":"Donggeng Liu","is_ca":false},{"name":"Zefei Jiang","is_ca":false},{"name":"V. Benešová","is_ca":false},{"name":"Martin Šmakal","is_ca":false},{"name":"Petra Garnolova","is_ca":false},{"name":"Anne‐Sophie Vesper","is_ca":false},{"name":"Monika Neumann","is_ca":false},{"name":"Wolfgang Janni","is_ca":false},{"name":"Cornelia Liedtke","is_ca":false},{"name":"Dorothea Fischer","is_ca":false},{"name":"Eva‐Maria Grischke","is_ca":false},{"name":"Dietmar Seeger","is_ca":false},{"name":"Volker Moebus","is_ca":false},{"name":"A. Prechtl","is_ca":false},{"name":"Juan Carlos Camara Toral","is_ca":false},{"name":"Alfonso Sánchez Muñoz","is_ca":false},{"name":"Sonia Gonzalez Jimenez","is_ca":false},{"name":"Beatriz Cirauqui","is_ca":false},{"name":"Mireia Margelí Vila","is_ca":false},{"name":"Norberto Batista López","is_ca":false},{"name":"José Ignacio Chacón","is_ca":false},{"name":"Miguel Angel de la Cruz Mora","is_ca":false},{"name":"Audrey Mailliez","is_ca":false},{"name":"Laurence Vanlemmens","is_ca":false},{"name":"Damien Pouessel","is_ca":false},{"name":"Marc Espié","is_ca":false},{"name":"John Conibear","is_ca":false},{"name":"Rebecca Roylance","is_ca":false},{"name":"Adrian Harnett","is_ca":false},{"name":"David Geffen","is_ca":false},{"name":"Enzo Maria Ruggeri","is_ca":false},{"name":"Teresa Gamucci","is_ca":false},{"name":"Cees J. van Groeningen","is_ca":false},{"name":"Renata Banaś","is_ca":false},{"name":"Niklas Loman","is_ca":false},{"name":"Necati Alkış","is_ca":false},{"name":"Ming‐Feng Hou","is_ca":false},{"name":"Amy Krie","is_ca":false},{"name":"Nandagopal Vrindavanam","is_ca":false},{"name":"Orion M. Howard","is_ca":false},{"name":"Dennis L. Citrin","is_ca":false},{"name":"Mark Morginstin","is_ca":false},{"name":"Ajit Desai","is_ca":false},{"name":"Ines J. Sanchez","is_ca":false},{"name":"David Allen Nixon","is_ca":false},{"name":"Patrick G. Beatty","is_ca":false},{"name":"Kathryn Edmiston","is_ca":false},{"name":"Marilyn McLaughlin","is_ca":false},{"name":"J.D. Eneman","is_ca":false},{"name":"Cynthia A. Lynch","is_ca":false},{"name":"Edward R. O’Brien","is_ca":false},{"name":"Justin Call","is_ca":false},{"name":"Keith S. Lanier","is_ca":false},{"name":"Alison Conlin","is_ca":false},{"name":"Donald Brooks","is_ca":false},{"name":"Kristi McIntyre","is_ca":false},{"name":"Marc Saltzman","is_ca":false},{"name":"Michael Castine","is_ca":false},{"name":"Gregory L. Ortega","is_ca":false},{"name":"Young Choi","is_ca":false},{"name":"Craig H. Reynolds","is_ca":false},{"name":"Frankie Ann Brescia","is_ca":false},{"name":"Rita Kramer","is_ca":false},{"name":"Aimee D. Kohn","is_ca":false},{"name":"John P. Micha","is_ca":false},{"name":"Jessica Rhee","is_ca":false},{"name":"Satish Shah","is_ca":false},{"name":"David Riseberg","is_ca":false},{"name":"W. K. Patterson","is_ca":false},{"name":"Jean-Paul Salmon","is_ca":false},{"name":"Chantal André","is_ca":false},{"name":"Alain Bols","is_ca":false},{"name":"Randal D’hondt","is_ca":false},{"name":"Sylvie Luce","is_ca":false},{"name":"Claire Nouwynck","is_ca":false},{"name":"Gino Pelgrims","is_ca":false},{"name":"Vincent R. Richard","is_ca":false},{"name":"Johan Verschuere","is_ca":false},{"name":"Kurt Geldhof","is_ca":false},{"name":"Clemens B. Caspar","is_ca":false},{"name":"Rongcheng Luo","is_ca":false},{"name":"Otakar Bednařík","is_ca":false},{"name":"Kathrin Schwedler","is_ca":false},{"name":"Marcus Schmidt","is_ca":false},{"name":"Romy Neumeister","is_ca":false},{"name":"Joachim Bischoff","is_ca":false},{"name":"Brigitte Rack","is_ca":false},{"name":"Roland Repp","is_ca":false},{"name":"Stefan Fries","is_ca":false},{"name":"Ralf Adrion","is_ca":false},{"name":"Volkmar Schulz","is_ca":false},{"name":"Peter Klare","is_ca":false},{"name":"M. Danei","is_ca":false},{"name":"Dirk P Ossenbühl","is_ca":false},{"name":"Jakob Manfred Kusche","is_ca":false},{"name":"Frank Griesinger","is_ca":false},{"name":"José Manuel Baena Cañada","is_ca":false},{"name":"Purificación Martínez del Prado","is_ca":false},{"name":"D. Machover","is_ca":false},{"name":"Didier Mayeur","is_ca":false},{"name":"Nathalie Trufflandier","is_ca":false},{"name":"Valérie Delecroix","is_ca":false},{"name":"Mireille Mousseau","is_ca":false},{"name":"Marie‐Ange Mouret‐Reynier","is_ca":false},{"name":"Jean‐Marc Nabholtz","is_ca":false},{"name":"A.D. Chetiyawardana","is_ca":false},{"name":"Christos N. Papandreou","is_ca":false},{"name":"Lajos Hornyák","is_ca":false},{"name":"Zsolt Faluhelyi","is_ca":false},{"name":"Erzsebet Simo","is_ca":false},{"name":"Mario Di Palma","is_ca":false},{"name":"Francesco Cognetti","is_ca":false},{"name":"G. Gorzegno","is_ca":false},{"name":"Luigi Dogliotti","is_ca":false},{"name":"Cesare Gridelli","is_ca":false},{"name":"Alfredo Falcone","is_ca":false},{"name":"Héctor Soto Parrà","is_ca":false},{"name":"Calogero Buscarino","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Benito Sanchez Llamas","is_ca":false},{"name":"Wouter Dercksen","is_ca":false},{"name":"Franciscus Erdkamp","is_ca":false},{"name":"Jan B. Ruit","is_ca":false},{"name":"Hans J. Braun","is_ca":false},{"name":"J. Portielje","is_ca":false},{"name":"Aydın Çiltaş","is_ca":false},{"name":"Süleyman Buyukberber","is_ca":false},{"name":"Mustafa Beneklı","is_ca":false},{"name":"Andrew J. Zahalsky","is_ca":false},{"name":"Rebecca Jaslow","is_ca":false},{"name":"Gary W. Thomas","is_ca":false},{"name":"Archana Maini","is_ca":false},{"name":"Israel Wiznitzer","is_ca":false},{"name":"Ali Khojasteh","is_ca":false},{"name":"Manuel F. Gonzalez","is_ca":false},{"name":"Lynn R. Kong","is_ca":false},{"name":"Aruna Padmanabhan","is_ca":false},{"name":"William A. Conkright","is_ca":false},{"name":"Sandra M. Swain","is_ca":false},{"name":"Douglas Faig","is_ca":false},{"name":"Kirti Jain","is_ca":false},{"name":"Ronald Yanagihara","is_ca":false},{"name":"Yvonne Ottaviano","is_ca":false},{"name":"Andrew Delmas","is_ca":false},{"name":"Heather A. Steele","is_ca":false},{"name":"Gordon K. Rainey","is_ca":false},{"name":"Penelope J. Harris","is_ca":false},{"name":"Jason K. Burris","is_ca":false},{"name":"Erik J. Rupard","is_ca":false},{"name":"E.Z.Z. Tan","is_ca":false},{"name":"Pat W. Whitworth","is_ca":false},{"name":"A. Bova","is_ca":false},{"name":"Ian C. Anderson","is_ca":false},{"name":"Mihran Shirinian","is_ca":false},{"name":"C Tin-U","is_ca":false},{"name":"Timothy J. O’Rourke","is_ca":false},{"name":"Michael S. Roberts","is_ca":false},{"name":"Michael Francisco","is_ca":false},{"name":"A. Scott Pierson","is_ca":false},{"name":"Peter D. Byeff","is_ca":false},{"name":"Peter A. Kovach","is_ca":false},{"name":"J. R. Caton","is_ca":false},{"name":"Mark U. Rarick","is_ca":false},{"name":"William G. Schimidt","is_ca":false},{"name":"Alison Stopeck","is_ca":false},{"name":"Rachel Swart","is_ca":false},{"name":"Maria Regina Carrillo Flores","is_ca":false},{"name":"Carlos Alemany","is_ca":false},{"name":"Brennely Lozada","is_ca":false},{"name":"Paul L. Weinstein","is_ca":false},{"name":"Wei Wang","is_ca":false},{"name":"Michael Porubcin","is_ca":false},{"name":"David M. Ellison","is_ca":false},{"name":"George F. Geils","is_ca":false},{"name":"Edgardo Rivera","is_ca":false},{"name":"Mahmoud Charif","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09916280515671266,"gpt":0.4624950642930083,"spread":0.3633322591362956,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003656813,0.002207806,0.005050621,0.0004660369,0.0004583111,0.00159487,0.00126331,0.002285412,0.00514436],"category_scores_gemma":[0.003024952,0.0006953563,0.004394197,0.0005563044,0.001497472,0.002510563,0.0005829897,0.004596834,0.001039049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009729541,"about_ca_system_score_gemma":0.0008754494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009790853,"about_ca_topic_score_gemma":0.002201162,"domain_scores_codex":[0.9986429,0.0007343357,0.00008698038,0.0002296667,0.00008360564,0.0002225157],"domain_scores_gemma":[0.9985062,0.0004913181,0.0003563138,0.0001733728,0.00009142102,0.000381346],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9888529,0.001132547,0.0003108578,0.0005127686,0.001520717,0.00002923269,0.00003136859,0.0003042626,0.0007890726,0.00007557468,0.0004000105,0.006040598],"study_design_scores_gemma":[0.9722939,0.02425778,0.001388479,0.00004123815,0.0009188283,0.00003709464,0.00002508245,0.0002843897,0.0001883302,0.0001750962,0.0003718367,0.00001803378],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762468,0.01515486,0.001290504,0.00104998,0.001055766,0.001706925,0.00142889,0.0001924126,0.001873843],"genre_scores_gemma":[0.9867225,0.004634472,0.001119351,0.00106643,0.0004391076,0.001397973,0.001436515,0.00004223547,0.003141293],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00514436,"threshold_uncertainty_score":0.01933932,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2264000214","doi":"10.1016/s1470-2045(15)00551-3","title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":565,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Puma Biotechnology","keywords":"Neratinib; Medicine; Trastuzumab; Internal medicine; Breast cancer; Oncology; Placebo; Regimen; Cancer; Metastatic breast cancer; Adjuvant therapy; Gynecology; Pathology","authors":[{"name":"Arlene Chan","is_ca":false},{"name":"Suzette Delaloge","is_ca":false},{"name":"Frankie A. Holmes","is_ca":false},{"name":"Beverly Moy","is_ca":false},{"name":"Hiroji Iwata","is_ca":false},{"name":"Vernon Harvey","is_ca":false},{"name":"Nicholas J. Robert","is_ca":false},{"name":"Tajana Silovski","is_ca":false},{"name":"Erhan Gökmen","is_ca":false},{"name":"Gϋnter von Minckwitz","is_ca":false},{"name":"Bent Ejlertsen","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Janine Mansi","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Michael Gnant","is_ca":false},{"name":"Marc Buyse","is_ca":false},{"name":"Ira Gore","is_ca":false},{"name":"John W. Smith","is_ca":false},{"name":"Graydon Harker","is_ca":false},{"name":"Norikazu Masuda","is_ca":false},{"name":"Katarína Petráková","is_ca":false},{"name":"Ángel Guerrero Zotano","is_ca":false},{"name":"Nicholas Iannotti","is_ca":false},{"name":"Gladys Rodriguez","is_ca":false},{"name":"Pierfrancesco Tassone","is_ca":false},{"name":"Alvin Wong","is_ca":false},{"name":"Richard Bryce","is_ca":false},{"name":"Yining Ye","is_ca":false},{"name":"Bin Yao","is_ca":false},{"name":"Miguel Martín","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04734896813518842,"gpt":0.3900358492526455,"spread":0.3426868811174571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001888721,0.002048192,0.00392972,0.0003642701,0.0003985617,0.001190032,0.001040033,0.001955599,0.006115931],"category_scores_gemma":[0.001813224,0.0006418989,0.002398052,0.0004473402,0.00122361,0.001734248,0.0004992737,0.003699146,0.001160924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006621577,"about_ca_system_score_gemma":0.0007472446,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006303002,"about_ca_topic_score_gemma":0.00177684,"domain_scores_codex":[0.9993706,0.0003125349,0.00004427225,0.0001202581,0.00003978604,0.0001124714],"domain_scores_gemma":[0.9993926,0.0001683336,0.0001391262,0.00006395531,0.00003728877,0.0001986176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9839544,0.001807635,0.0002983326,0.0008058246,0.001067818,0.00003866036,0.0000430554,0.0002833525,0.001458157,0.0001084207,0.0007803575,0.00935402],"study_design_scores_gemma":[0.9789948,0.01907939,0.0006909075,0.00002465962,0.0003318458,0.00003057579,0.00001609167,0.0001566568,0.000148238,0.0001211176,0.0003945322,0.00001122758],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791494,0.01099275,0.0009666611,0.001250608,0.00114067,0.002563554,0.001314681,0.0002169418,0.002404707],"genre_scores_gemma":[0.9827034,0.005118908,0.001378152,0.001517634,0.0004958475,0.002419985,0.001422882,0.00003898927,0.004904132],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006115931,"threshold_uncertainty_score":0.02045989,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2152647863","doi":"10.1200/jco.2007.13.5467","title":"Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":545,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute","keywords":"Trastuzumab; Medicine; Ejection fraction; Heart failure; Internal medicine; Breast cancer; Cyclophosphamide; Cardiac function curve; Cardiology; Cardiotoxicity; Oncology; Paclitaxel; Cancer; Surgery; Chemotherapy","authors":[{"name":"Edith A. Perez","is_ca":true},{"name":"Vera J. Suman","is_ca":true},{"name":"Nancy E. Davidson","is_ca":true},{"name":"George W. Sledge","is_ca":true},{"name":"Peter A. Kaufman","is_ca":true},{"name":"Clifford A. Hudis","is_ca":true},{"name":"Silvana Martino","is_ca":true},{"name":"Julie R. Gralow","is_ca":true},{"name":"Shaker R. Dakhil","is_ca":true},{"name":"James N. Ingle","is_ca":true},{"name":"Eric P. Winer","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Bernard J. Gersh","is_ca":true},{"name":"Allan S. Jaffe","is_ca":true},{"name":"Richard J. Rodeheffer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1113342310621078,"gpt":0.4752544723547745,"spread":0.3639202412926667,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002481657,0.0006488168,0.0009311892,0.0002429225,0.000286368,0.0005453315,0.000566269,0.0007276644,0.002355726],"category_scores_gemma":[0.001851214,0.000279771,0.0008506638,0.0003184492,0.0005835239,0.0003866931,0.0002933138,0.001466264,0.0002995184],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009933216,"about_ca_system_score_gemma":0.001176035,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001381335,"about_ca_topic_score_gemma":0.004711665,"domain_scores_codex":[0.9986449,0.001045424,0.0000345714,0.0001145966,0.0000852082,0.0000752828],"domain_scores_gemma":[0.9987362,0.0003256209,0.0004571145,0.00009815881,0.00006637609,0.0003165416],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.952344,0.004922639,0.008308463,0.000343797,0.001023098,0.00006202376,0.00006741939,0.000956213,0.003161184,0.0001528214,0.001916542,0.02674165],"study_design_scores_gemma":[0.7874666,0.1345733,0.06927223,0.0001643734,0.001606645,0.000246792,0.00005518808,0.001907847,0.001153819,0.0003559184,0.003165274,0.00003204772],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950811,0.002439423,0.0001006227,0.0004913723,0.00006968514,0.0003252855,0.0002414752,0.00001216208,0.001238877],"genre_scores_gemma":[0.9956285,0.001055377,0.0003175136,0.0005256957,0.0001633446,0.000465278,0.0007337534,0.000007151651,0.001103478],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002481657,"threshold_uncertainty_score":0.01312441,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2768649895","doi":"10.1016/s1470-2045(17)30716-7","title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":529,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Jewish General Hospital; McGill University","funders":"Johnson and Johnson; F. Hoffmann-La Roche; Eli Lilly and Company","keywords":"Pertuzumab; Medicine; Trastuzumab; Trastuzumab emtansine; Docetaxel; Oncology; Internal medicine; Breast cancer; Carboplatin; Regimen; Neoadjuvant therapy; Metastatic breast cancer; Cancer; Chemotherapy","authors":[{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"W. Fraser Symmans","is_ca":false},{"name":"Kyung Hae Jung","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Alastair M. Thompson","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Vicente Valero","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Hans Wildiers","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Jean-François Boileau","is_ca":true},{"name":"Matthias W. Beckmann","is_ca":false},{"name":"Karen Afenjar","is_ca":false},{"name":"Rodrigo Fresco","is_ca":false},{"name":"Hans‐Joachim Helms","is_ca":false},{"name":"Jin Xu","is_ca":false},{"name":"Yvonne G. Lin","is_ca":false},{"name":"Joseph A. Sparano","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09179359523436297,"gpt":0.4422125994061898,"spread":0.3504190041718268,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003502623,0.001270149,0.002595059,0.0003341782,0.0005284852,0.0009900918,0.0008576257,0.001700245,0.004709816],"category_scores_gemma":[0.002653496,0.0006493868,0.001816381,0.0003760368,0.001364842,0.001313275,0.0005947174,0.002301665,0.0006645056],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009450912,"about_ca_system_score_gemma":0.001919026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007508401,"about_ca_topic_score_gemma":0.00226937,"domain_scores_codex":[0.9984067,0.001050591,0.00009102045,0.0001901706,0.000076545,0.0001850211],"domain_scores_gemma":[0.9982352,0.0005367089,0.0003806229,0.0001475712,0.00009002868,0.0006096984],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9860747,0.004888379,0.0003148972,0.0002564182,0.0002532214,0.00002070734,0.00005301879,0.0002452843,0.001372729,0.00006182354,0.0003446593,0.006114085],"study_design_scores_gemma":[0.9293236,0.06873528,0.0008405058,0.00002216018,0.000159355,0.00002467182,0.0000136456,0.000203319,0.0001671423,0.00009870732,0.0003998876,0.00001172367],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9868058,0.00280779,0.0005574957,0.0007015166,0.0004605748,0.006340205,0.000573152,0.00007408715,0.001679535],"genre_scores_gemma":[0.981266,0.001766638,0.002545382,0.001268484,0.0004835172,0.009640353,0.000724344,0.00002018453,0.002285256],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004709816,"threshold_uncertainty_score":0.01852387,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2059715478","doi":"10.1016/j.cell.2012.12.030","title":"Architecture and Membrane Interactions of the EGF Receptor","year":2013,"lang":"en","type":"article","venue":"Cell","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":525,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Howard Hughes Medical Institute","keywords":"Extracellular; Transmembrane protein; Biology; Transmembrane domain; Biophysics; Cell biology; Intracellular; Cell membrane; Kinase; Membrane; Biochemistry; Receptor","authors":[{"name":"Anton Arkhipov","is_ca":false},{"name":"Yibing Shan","is_ca":false},{"name":"Rahul Das","is_ca":false},{"name":"Nicholas Endres","is_ca":false},{"name":"Michael P. Eastwood","is_ca":false},{"name":"David E. Wemmer","is_ca":false},{"name":"John Kuriyan","is_ca":false},{"name":"David E. Shaw","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01952346414713911,"gpt":0.3043025665013322,"spread":0.2847791023541931,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006120172,0.0001583409,0.0001003353,0.0001864415,0.0004165114,0.0005558179,0.0002524299,0.000277572,0.001203995],"category_scores_gemma":[0.0001297382,0.0001401582,0.00009832398,0.0001387436,0.0002119332,0.000569264,0.0002289178,0.0003858689,0.0004419829],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004690587,"about_ca_system_score_gemma":0.0002155362,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001326373,"about_ca_topic_score_gemma":0.001450491,"domain_scores_codex":[0.9999607,0.000007671933,0.000001587302,0.000006672225,0.000009113392,0.00001440313],"domain_scores_gemma":[0.9999644,0.000006036142,0.000007076495,0.000002428846,0.000009402106,0.00001070326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001870947,0.00002246762,0.001450736,0.00007043037,0.00001277297,0.0002082205,0.0001132563,0.001206686,0.9799668,0.0116502,0.0003241991,0.004787141],"study_design_scores_gemma":[0.00005827873,0.0004624433,0.06938446,0.00009948929,0.0001089525,0.002269836,0.001894709,0.06631254,0.7987333,0.02452629,0.0360506,0.0000990915],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9900686,0.00178293,0.002780064,0.0002892845,0.00001504241,0.000004322062,0.0000622417,0.00002664154,0.004970926],"genre_scores_gemma":[0.9963287,0.000843374,0.0006480868,0.0000532922,0.000007507507,0.000002848667,0.0001031361,0.000006922297,0.002006177],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001326373,"threshold_uncertainty_score":0.004027724,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2078881615","doi":"10.1056/nejmoa054504","title":"<i>HER2</i> and Responsiveness of Breast Cancer to Adjuvant Chemotherapy","year":2006,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":508,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; Lunenfeld-Tanenbaum Research Institute; McMaster University; Queen's University; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anthracycline; Oncology; Breast cancer; Internal medicine; Chemotherapy; Adjuvant; Adjuvant chemotherapy; Cancer; Cancer research; Human Epidermal Growth Factor Receptor 2","authors":[{"name":"Kathleen I. Pritchard","is_ca":true},{"name":"Lois E. Shepherd","is_ca":true},{"name":"Frances P. O’Malley","is_ca":true},{"name":"Irene L. Andrulis","is_ca":true},{"name":"Dongsheng Tu","is_ca":true},{"name":"Vivien Bramwell","is_ca":true},{"name":"Mark N. Levine","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01893375892135406,"gpt":0.3470915491465274,"spread":0.3281577902251733,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003027258,0.0002757122,0.0005880144,0.0003049637,0.0001327698,0.0003924013,0.0003469168,0.0006049411,0.001529944],"category_scores_gemma":[0.003743224,0.0001530368,0.000517616,0.000295435,0.0004812165,0.0001967649,0.0001579838,0.0005298432,0.0001357639],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003276121,"about_ca_system_score_gemma":0.000384476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000475219,"about_ca_topic_score_gemma":0.0005345891,"domain_scores_codex":[0.9991647,0.000529803,0.00005973446,0.00008664077,0.00008396014,0.00007516413],"domain_scores_gemma":[0.9964926,0.002157715,0.000845207,0.000114597,0.00008521257,0.0003047955],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.558068,0.002894734,0.3688338,0.0009340928,0.002465545,0.0001724859,0.00007092131,0.001528954,0.007447302,0.0001166269,0.001179126,0.05628842],"study_design_scores_gemma":[0.08850518,0.1347902,0.7556041,0.0003317484,0.005064578,0.001498408,0.00007719381,0.002676424,0.006939732,0.0004824204,0.003993157,0.00003687432],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945917,0.004168363,0.000120705,0.000184668,0.00002946187,0.0001179819,0.0002004015,0.000007519045,0.0005793453],"genre_scores_gemma":[0.9982952,0.0006943407,0.0001919737,0.0001626673,0.00008094646,0.0001040173,0.0003372116,0.000002132541,0.0001315018],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003027258,"threshold_uncertainty_score":0.01600987,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2080518844","doi":"10.1158/1078-0432.ccr-07-0701","title":"Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>In vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network","year":2007,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":506,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Immunovaccine (Canada)","funders":"National Cancer Institute","keywords":"Trastuzumab; Gefitinib; Lapatinib; Erlotinib; Cancer research; Epidermal growth factor receptor; ErbB; In vivo; Epidermal growth factor; Growth factor receptor; Biology; Cancer; Receptor; Medicine; Breast cancer; Internal medicine","authors":[{"name":"Christoph A. Ritter","is_ca":true},{"name":"Marianela Pérez-Torres","is_ca":true},{"name":"Cammie Rinehart","is_ca":true},{"name":"Marta Guix","is_ca":true},{"name":"Teresa C. Dugger","is_ca":true},{"name":"Jeffrey A. Engelman","is_ca":false},{"name":"Carlos L. Arteaga","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1265625171483836,"gpt":0.4760326595411657,"spread":0.3494701423927821,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002293722,0.0003260893,0.0003554881,0.0001680138,0.0001664771,0.0003453982,0.0002172447,0.0002286686,0.0025151],"category_scores_gemma":[0.0001608868,0.0001711537,0.0002443493,0.0003381744,0.0001601712,0.0001496271,0.0001530038,0.0005305874,0.00112948],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003206564,"about_ca_system_score_gemma":0.0002297458,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001645104,"about_ca_topic_score_gemma":0.001368639,"domain_scores_codex":[0.9997923,0.00002826615,0.00002471972,0.00003783782,0.00006886,0.0000480296],"domain_scores_gemma":[0.9998798,0.00002702914,0.00002743461,0.00002875981,0.00002006575,0.00001697648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002996914,0.0001781708,0.003665048,0.00006351378,0.00002526187,0.0001976912,0.00004523754,0.00009048021,0.9911962,0.0001422078,0.0003031469,0.003793422],"study_design_scores_gemma":[0.0001156973,0.001633941,0.03108315,0.00001100383,0.00008805179,0.003226685,0.00007590857,0.0008834986,0.9548295,0.00004801119,0.007994322,0.00001023055],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931774,0.001695427,0.001481091,0.00008827243,0.00002442337,0.00009057586,0.0009949676,0.00007831118,0.00236961],"genre_scores_gemma":[0.9860838,0.001551487,0.003200153,0.0001001681,0.00001855778,0.000104319,0.004537757,0.00003288213,0.004370875],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0025151,"threshold_uncertainty_score":0.008413851,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2165824128","doi":"10.1200/jco.2005.04.1764","title":"Randomized Phase III Study of Trastuzumab, Paclitaxel, and Carboplatin Compared With Trastuzumab and Paclitaxel in Women With HER-2–Overexpressing Metastatic Breast Cancer","year":2006,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":484,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Metastatic breast cancer; Carboplatin; Oncology; Breast cancer; Internal medicine; Randomized controlled trial; Chemotherapy; Cancer; Cisplatin","authors":[{"name":"Nicholas J. Robert","is_ca":true},{"name":"Brian Leyland‐Jones","is_ca":true},{"name":"Lina Asmar","is_ca":true},{"name":"Robert J. Belt","is_ca":true},{"name":"D. Ilegbodu","is_ca":true},{"name":"David Loesch","is_ca":true},{"name":"Robert N. Raju","is_ca":true},{"name":"Elizabeth Valentine","is_ca":true},{"name":"Robert M. Sayre","is_ca":true},{"name":"Melody Cobleigh","is_ca":true},{"name":"Kathy S. Albain","is_ca":true},{"name":"Cecelia McCullough","is_ca":true},{"name":"Lea Fuchs","is_ca":true},{"name":"Dennis J. Slamon","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1106490242730566,"gpt":0.4916220190092541,"spread":0.3809729947361974,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003437147,0.002018047,0.003682378,0.0005254386,0.0005875895,0.001139574,0.001244923,0.001889086,0.005370446],"category_scores_gemma":[0.003872285,0.001055559,0.001754363,0.0005663902,0.001654539,0.001117624,0.0005128246,0.004150657,0.001093022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001229535,"about_ca_system_score_gemma":0.002057143,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001345629,"about_ca_topic_score_gemma":0.003101069,"domain_scores_codex":[0.9985814,0.0009997748,0.00005642172,0.0001574565,0.00008090984,0.0001239902],"domain_scores_gemma":[0.9975414,0.0008238904,0.0005811871,0.0001882004,0.0001288174,0.0007365576],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9857982,0.005863592,0.0004408217,0.0001456911,0.0004995629,0.00001975349,0.00002899009,0.0002655509,0.001083704,0.00004671115,0.0004634479,0.005343945],"study_design_scores_gemma":[0.9627957,0.03575519,0.0005832045,0.00000829281,0.0001682853,0.00001545585,0.000007226278,0.0002187382,0.0001434517,0.00005593946,0.0002434719,0.000004985483],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9818917,0.004467188,0.00123552,0.001469083,0.001004379,0.006773058,0.00123188,0.0001511916,0.001776057],"genre_scores_gemma":[0.9765537,0.002654003,0.002890273,0.002207387,0.0008949859,0.009694465,0.00154582,0.00005073023,0.003508643],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005370446,"threshold_uncertainty_score":0.01817757,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3194861850","doi":"10.3390/jpm11080808","title":"Breast Cancer Treatments: Updates and New Challenges","year":2021,"lang":"en","type":"review","venue":"Journal of Personalized Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":473,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Medicine; Breast cancer; Estrogen receptor; Cancer; Immunotherapy; Oncology; Targeted therapy; Radiation therapy; Triple-negative breast cancer; Internal medicine; Epidermal growth factor receptor; Bioinformatics; Cancer research; Biology","authors":[{"name":"Anna Burguin","is_ca":true},{"name":"Caroline Diorio","is_ca":true},{"name":"Francine Durocher","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2674732368484319,"gpt":0.4993552194370062,"spread":0.2318819825885742,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001007249,0.0007095273,0.001233854,0.001678958,0.0003542222,0.001380055,0.0008758769,0.001312553,0.006738023],"category_scores_gemma":[0.001649858,0.0002696668,0.0006512351,0.001506446,0.0005084201,0.001971623,0.0007843897,0.002912551,0.002696418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008452028,"about_ca_system_score_gemma":0.001504763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001024902,"about_ca_topic_score_gemma":0.002340756,"domain_scores_codex":[0.9995874,0.0000893425,0.00005593071,0.00005330196,0.0001781987,0.00003598414],"domain_scores_gemma":[0.9991173,0.0004287106,0.00007536828,0.00002605438,0.0002900021,0.00006253818],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005410563,0.00006184092,0.0001090888,0.01086298,0.00005699042,0.0001123285,0.0000570524,0.0002325445,0.0006864564,0.005082306,0.07118059,0.9115037],"study_design_scores_gemma":[0.00001071802,0.00005394511,0.0002256605,0.002882697,0.00005132557,0.0005359337,0.00004259789,0.00006378019,0.0001160448,0.001885495,0.9941224,0.00000943474],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009067359,0.9961379,0.0001298891,0.001552065,0.0006890993,0.000005172497,0.00002488711,0.00001299855,0.001357189],"genre_scores_gemma":[0.0004926458,0.9970772,0.0002088167,0.0008015854,0.0006450325,0.000005681588,0.00004916815,0.000002918562,0.0007169909],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.006738023,"threshold_uncertainty_score":0.02254099,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2745112655","doi":"10.1007/978-1-4939-7219-7_1","title":"ErbB Receptors and Cancer","year":2017,"lang":"en","type":"review","venue":"Methods in molecular biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":431,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"ErbB; Receptor tyrosine kinase; ERBB3; ERBB4; Cancer research; Receptor; Epidermal growth factor receptor; Biology; Epidermal growth factor; Signal transduction; Neuregulin; Tyrosine kinase; Growth factor receptor; Cell biology; Biochemistry","authors":[{"name":"Zhixiang Wang","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3336806821133151,"gpt":0.6622974962907782,"spread":0.3286168141774631,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009013785,0.001466212,0.00166635,0.002871705,0.000321227,0.001697016,0.001037977,0.001330195,0.009041411],"category_scores_gemma":[0.001323788,0.0004601703,0.0004790355,0.002481167,0.0008542606,0.002362957,0.001679758,0.002886202,0.004826768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008958879,"about_ca_system_score_gemma":0.001844839,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008477321,"about_ca_topic_score_gemma":0.001872742,"domain_scores_codex":[0.999649,0.00006905524,0.00004204344,0.00004619797,0.0001505075,0.00004309958],"domain_scores_gemma":[0.999643,0.0001604374,0.00004675077,0.00002021738,0.00008427603,0.00004544001],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007398371,0.0000597454,0.0000849334,0.01105909,0.00007058524,0.0001087463,0.00006159332,0.0002680781,0.00112542,0.007075954,0.09410007,0.8859118],"study_design_scores_gemma":[0.00001781901,0.00003030792,0.0001692366,0.00206243,0.00005850769,0.000328844,0.00002702819,0.00005168527,0.0002102677,0.003218307,0.9938154,0.00001022678],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000043328,0.9967082,0.0001988171,0.0004550056,0.0008827741,0.000007191787,0.00002254128,0.00001238843,0.001669657],"genre_scores_gemma":[0.000484766,0.9958556,0.0002619569,0.0004702287,0.0008214269,0.00001125232,0.00004313409,0.000003028295,0.002048592],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009041411,"threshold_uncertainty_score":0.0302465,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2156373035","doi":"10.1021/cb500129t","title":"Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?","year":2014,"lang":"en","type":"review","venue":"ACS Chemical Biology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":428,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Canadian Institutes of Health Research; Wellcome Trust","keywords":"Small molecule; Drug discovery; Kinase; Binding site; Chemistry; Stereochemistry; Active site; Plasma protein binding; Biophysics; Enzyme; Combinatorial chemistry; Biochemistry; Biology","authors":[{"name":"Zheng Zhao","is_ca":false},{"name":"Hong Wu","is_ca":false},{"name":"Li Wang","is_ca":false},{"name":"Yi Liu","is_ca":false},{"name":"Stefan Knapp","is_ca":false},{"name":"Qingsong Liu","is_ca":false},{"name":"Nathanael S. Gray","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1308690158421731,"gpt":0.4185566617117618,"spread":0.2876876458695887,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003536801,0.0006745996,0.00108034,0.0009492632,0.0002454479,0.0009156979,0.0009458651,0.0007504181,0.003085321],"category_scores_gemma":[0.0002298687,0.0003141359,0.000456797,0.0009840741,0.0005138894,0.001458962,0.0005701627,0.001320477,0.002756782],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004506387,"about_ca_system_score_gemma":0.0005374899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004602287,"about_ca_topic_score_gemma":0.001089299,"domain_scores_codex":[0.9998919,0.00001811951,0.000007972922,0.00002231337,0.00003940859,0.00002022557],"domain_scores_gemma":[0.9999322,0.00001843686,0.00001297028,0.000005344831,0.00001924557,0.00001185703],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009783224,0.0001148192,0.0002419181,0.009417305,0.00009897338,0.0004385528,0.0001363171,0.0009212997,0.02745189,0.02601893,0.0264326,0.9086295],"study_design_scores_gemma":[0.00003195382,0.0002912431,0.0003805263,0.001209081,0.0000742535,0.002027489,0.0000736368,0.0003992866,0.005495705,0.006011841,0.9839731,0.00003178629],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001537397,0.9853716,0.003272386,0.0008731115,0.0003554759,0.00003203349,0.00005988766,0.00006653389,0.008431493],"genre_scores_gemma":[0.007010276,0.9858372,0.002306978,0.0006715449,0.0002136532,0.00003003861,0.00007088938,0.000008280977,0.003851062],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003085321,"threshold_uncertainty_score":0.01032138,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2994917610","doi":"10.1200/jco.19.01455","title":"NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":420,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; McGill University","funders":"National Cancer Institute; American Society of Clinical Oncology; Amgen; Pfizer; Eli Lilly and Company; Genentech","keywords":"Trastuzumab; Medicine; Oncology; Internal medicine; Breast cancer; Hazard ratio; Cyclophosphamide; Docetaxel; Chemotherapy; Immunohistochemistry; Adjuvant; Cancer; Confidence interval","authors":[{"name":"Louis Fehrenbacher","is_ca":false},{"name":"Reena S. Cecchini","is_ca":false},{"name":"Charles E. Geyer","is_ca":false},{"name":"Priya Rastogi","is_ca":false},{"name":"Joseph P. Costantino","is_ca":false},{"name":"James N. Atkins","is_ca":false},{"name":"John Crown","is_ca":false},{"name":"Jonathan Polikoff","is_ca":false},{"name":"Jean-François Boileau","is_ca":true},{"name":"Louise Provencher","is_ca":true},{"name":"Christopher Stokoe","is_ca":false},{"name":"Timothy D. Moore","is_ca":false},{"name":"André Robidoux","is_ca":true},{"name":"Patrick J. Flynn","is_ca":false},{"name":"Virginia F. Borges","is_ca":false},{"name":"Kathy S. Albain","is_ca":false},{"name":"Sandra M. Swain","is_ca":false},{"name":"Soonmyung Paik","is_ca":false},{"name":"Eleftherios P. Mamounas","is_ca":false},{"name":"Norman Wolmark","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1163470475283686,"gpt":0.5119909698977256,"spread":0.3956439223693571,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001894626,0.001399752,0.002115537,0.0004554611,0.0003371761,0.00075574,0.0007198509,0.001251845,0.004480266],"category_scores_gemma":[0.001522979,0.0005431481,0.001367611,0.0004180789,0.001194578,0.0006450173,0.0003738207,0.002419976,0.0006681312],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001036783,"about_ca_system_score_gemma":0.00159501,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001911071,"about_ca_topic_score_gemma":0.004261418,"domain_scores_codex":[0.9991725,0.0005549965,0.00003383696,0.00009166595,0.00005168424,0.00009532714],"domain_scores_gemma":[0.9991811,0.0001995419,0.0001927181,0.00005999286,0.00004192065,0.0003246795],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9848493,0.003458472,0.0007574642,0.0001679061,0.0004046018,0.00002096909,0.00002428025,0.0003438707,0.001535653,0.0001089451,0.0005663671,0.007762131],"study_design_scores_gemma":[0.9445882,0.05200861,0.001666587,0.00002109678,0.0003297252,0.00002384469,0.00001177551,0.0003760117,0.0002975606,0.0001664994,0.0005027129,0.000007395058],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870744,0.003079864,0.0005204659,0.0008486853,0.0004446816,0.004349429,0.001134002,0.00008327032,0.002465311],"genre_scores_gemma":[0.9860771,0.002099636,0.001283655,0.001282589,0.0003870505,0.004271238,0.001348937,0.00001991139,0.003229735],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004480266,"threshold_uncertainty_score":0.01498801,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2055235037","doi":"10.1016/s1470-2045(13)70411-x","title":"Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial","year":2013,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":386,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre; Jewish General Hospital; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"GlaxoSmithKline","keywords":"Medicine; Lapatinib; Trastuzumab; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Oncology; Population; Pertuzumab; Cyclophosphamide; Chemotherapy; Surgery; Clinical trial; Cancer","authors":[{"name":"André Robidoux","is_ca":true},{"name":"Gong Tang","is_ca":false},{"name":"Priya Rastogi","is_ca":false},{"name":"Charles E. Geyer","is_ca":false},{"name":"Catherine A. Azar","is_ca":false},{"name":"James N. Atkins","is_ca":false},{"name":"Louis Fehrenbacher","is_ca":false},{"name":"Harry D. Bear","is_ca":false},{"name":"Louis Baez-Diaz","is_ca":false},{"name":"Shakir Sarwar","is_ca":false},{"name":"Richard G. Margolese","is_ca":true},{"name":"William B. Farrar","is_ca":false},{"name":"Adam Brufsky","is_ca":false},{"name":"Henry R. Shibata","is_ca":true},{"name":"Hanna Bandos","is_ca":false},{"name":"Soonmyung Paik","is_ca":false},{"name":"Joseph P. Costantino","is_ca":false},{"name":"Sandra M. Swain","is_ca":false},{"name":"Eleftherios P. Mamounas","is_ca":false},{"name":"Norman Wolmark","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1888122349117266,"gpt":0.5311267806640083,"spread":0.3423145457522817,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002902753,0.003012743,0.003466259,0.0005485357,0.0006642403,0.001618227,0.001214802,0.002638284,0.01573076],"category_scores_gemma":[0.002774293,0.001123957,0.002971472,0.0006260817,0.002111041,0.001891475,0.0008813391,0.005380075,0.002626917],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001504785,"about_ca_system_score_gemma":0.002389364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001645587,"about_ca_topic_score_gemma":0.003587488,"domain_scores_codex":[0.9986635,0.0008098973,0.0000594453,0.0001782729,0.00007525535,0.0002136824],"domain_scores_gemma":[0.9986437,0.000372126,0.0002455811,0.0001311704,0.000058187,0.0005492497],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9881521,0.002560438,0.0001591288,0.0004001691,0.0003814218,0.00001828907,0.0000370339,0.0003136721,0.0008986545,0.00008954766,0.000885429,0.006104088],"study_design_scores_gemma":[0.9770733,0.02168532,0.0003179987,0.00002134031,0.0001273551,0.00001333474,0.00001016914,0.0001528336,0.00009225088,0.000137336,0.0003600343,0.0000087557],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9451752,0.0059107,0.00249766,0.002717505,0.001564461,0.02736668,0.005631763,0.0005317992,0.008604182],"genre_scores_gemma":[0.9320534,0.004234921,0.005419084,0.003495436,0.0006994734,0.03791285,0.004591351,0.0001298001,0.01146372],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01573076,"threshold_uncertainty_score":0.05262464,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2133208325","doi":"10.1093/annonc/mdh031","title":"Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","year":2003,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":384,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Princess Margaret Cancer Centre","funders":"","keywords":"Gemcitabine; Trastuzumab; Medicine; Internal medicine; Oncology; Chemotherapy; Cisplatin; Lung cancer; Breast cancer; Cancer","authors":[{"name":"U. Gatzemeier","is_ca":false},{"name":"G. Groth","is_ca":false},{"name":"Charles Butts","is_ca":false},{"name":"Nico van Zandwijk","is_ca":false},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Andrea Ardizzoni","is_ca":false},{"name":"Claire Barton","is_ca":false},{"name":"Parviz Ghahramani","is_ca":false},{"name":"Vera Hirsh","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09359131375202594,"gpt":0.4696181439327916,"spread":0.3760268301807656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001842693,0.002117045,0.004438248,0.0005564569,0.0006175005,0.001721217,0.0014541,0.002100389,0.01036151],"category_scores_gemma":[0.001897488,0.00111908,0.002086005,0.0006186733,0.002016773,0.001764854,0.0007225248,0.005438867,0.001830623],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001614388,"about_ca_system_score_gemma":0.001738047,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002000157,"about_ca_topic_score_gemma":0.004515097,"domain_scores_codex":[0.9992867,0.0003686637,0.00003489232,0.0001549095,0.00003654281,0.0001182428],"domain_scores_gemma":[0.9989077,0.0003001065,0.0001557664,0.0001228056,0.00005364254,0.000460006],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9803662,0.005577913,0.0003770733,0.0002965642,0.0006776552,0.00003117908,0.00004718967,0.0005851289,0.001554866,0.0001306648,0.000788043,0.009567631],"study_design_scores_gemma":[0.9717866,0.02651376,0.0005368865,0.0000119195,0.0002284911,0.00001575739,0.00001660448,0.0002373137,0.000171924,0.0001077244,0.0003655604,0.000007479276],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835777,0.003551341,0.000954034,0.001645088,0.001423309,0.00408207,0.001370457,0.000167541,0.003228445],"genre_scores_gemma":[0.9825944,0.002213171,0.001746982,0.001688357,0.000461312,0.003719523,0.001741681,0.00005551811,0.005779223],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01036151,"threshold_uncertainty_score":0.03466272,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2019184486","doi":"10.1016/s0896-6273(00)81176-9","title":"Regulation of Neuregulin Signaling by PSD-95 Interacting with ErbB4 at CNS Synapses","year":2000,"lang":"en","type":"article","venue":"Neuron","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":382,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Neuregulin; ERBB4; Neuregulin 1; Postsynaptic density; Long-term potentiation; Synaptic plasticity; Neuroscience; Postsynaptic potential; ErbB; Cell biology; Neurotransmission; Receptor tyrosine kinase; Biology; Signal transduction; Kinase; Chemistry; Receptor; Biochemistry","authors":[{"name":"Yang Z. Huang","is_ca":false},{"name":"Sandra Won","is_ca":false},{"name":"Declan W. Ali","is_ca":true},{"name":"Qiang Wang","is_ca":false},{"name":"Michael Tanowitz","is_ca":false},{"name":"Quansheng Du","is_ca":false},{"name":"Kenneth A. Pelkey","is_ca":true},{"name":"Da J. Yang","is_ca":false},{"name":"Wen‐Cheng Xiong","is_ca":false},{"name":"Michael W. Salter","is_ca":true},{"name":"Lin Mei","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02521958510381617,"gpt":0.3173303865495232,"spread":0.292110801445707,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001232677,0.0003378895,0.0002383178,0.0003261651,0.0004468096,0.0006602977,0.0005980862,0.0002891223,0.001599831],"category_scores_gemma":[0.0002028171,0.0001894049,0.0003503319,0.0001728583,0.0003015104,0.0005290686,0.0005471616,0.0005982669,0.0005946649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00104257,"about_ca_system_score_gemma":0.0002977435,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00144217,"about_ca_topic_score_gemma":0.002045805,"domain_scores_codex":[0.9998253,0.00001952784,0.000008858258,0.00002580976,0.00004727413,0.00007326584],"domain_scores_gemma":[0.9999392,0.000007746552,0.0000150684,0.000007690183,0.0000124019,0.00001798803],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003061419,0.0000380587,0.0006315631,0.00005311143,0.00002687619,0.0002690634,0.00003421693,0.000189928,0.9922022,0.0009449332,0.0001440255,0.005159948],"study_design_scores_gemma":[0.00005136136,0.00009569484,0.03125547,0.00001514323,0.00004423853,0.0006370157,0.0002003308,0.003646299,0.9613484,0.0008452103,0.001848552,0.00001231391],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9904082,0.003235365,0.002257508,0.0002004453,0.00003551788,0.000009029181,0.0001128491,0.00004591878,0.003695129],"genre_scores_gemma":[0.9957709,0.0008691241,0.0007325123,0.00002646811,0.000006101929,0.000007957975,0.0000939172,0.000008503282,0.00248456],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001599831,"threshold_uncertainty_score":0.007564425,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2144648936","doi":"10.1634/theoncologist.12-5-610","title":"Epidermal Growth Factor Receptor Inhibitor–Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management","year":2007,"lang":"en","type":"review","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":341,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Cancer Institute; BC Cancer Agency; Vrije Universiteit Amsterdam; Institut Claudius Regaud; Memorial Sloan-Kettering Cancer Center","keywords":"Medicine; Epidermal growth factor receptor; EGFR inhibitors; Cetuximab; Colorectal cancer; Toxicity; Grading (engineering); Quality of life (healthcare); Gefitinib; Cancer; Oncology; Internal medicine","authors":[{"name":"Thomas J. Lynch","is_ca":false},{"name":"Ed S. Kim","is_ca":false},{"name":"Beth Eaby","is_ca":false},{"name":"Jody S. Garey","is_ca":false},{"name":"Dennis P. West","is_ca":false},{"name":"Mario E. Lacouture","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2509656558099983,"gpt":0.5050140510855577,"spread":0.2540483952755594,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002950199,0.0009483678,0.002447513,0.002664061,0.0004620386,0.002170652,0.001684441,0.002184323,0.001371883],"category_scores_gemma":[0.002727805,0.0003269145,0.0006213221,0.003068009,0.001618184,0.00327215,0.0008790428,0.003774004,0.0009932261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001956535,"about_ca_system_score_gemma":0.002253563,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001420668,"about_ca_topic_score_gemma":0.002970516,"domain_scores_codex":[0.998908,0.0003955624,0.000163158,0.0001121045,0.0003694291,0.00005177884],"domain_scores_gemma":[0.9985387,0.0007312145,0.000184709,0.00004077628,0.0004135464,0.00009106861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000600071,0.00007309213,0.000306046,0.008363609,0.00006379673,0.0004498687,0.0001739414,0.0004605296,0.0006279314,0.008172874,0.03238411,0.9488642],"study_design_scores_gemma":[0.0000749563,0.0002051911,0.001860787,0.01087067,0.000108499,0.005551732,0.0006320067,0.0004576801,0.0003010094,0.01079213,0.9690934,0.00005187944],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001636941,0.995544,0.0003257813,0.002824935,0.000323734,0.00000522477,0.00000384238,0.000009082852,0.0007996495],"genre_scores_gemma":[0.001541405,0.9953295,0.0009462024,0.001168061,0.0006408101,0.00001113362,0.00001150336,0.000002422747,0.0003489224],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002950199,"threshold_uncertainty_score":0.01560235,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1966937303","doi":"10.1073/pnas.1014835108","title":"Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 <sup>+</sup> breast cancer patients","year":2011,"lang":"en","type":"article","venue":"Proceedings of the National Academy of Sciences","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":332,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Research Manitoba","funders":"National Cancer Institute; Instituto de Salud Carlos III; Breast Cancer Research Foundation","keywords":"Trastuzumab; Cancer research; Cyclin D; Cyclin E; Breast cancer; Cyclin E1; Cyclin D1; Cyclin A; Cyclin; Cyclin B; Cyclin A2; Cell cycle; Cancer; Biology; Medicine; Internal medicine","authors":[{"name":"Maurizio Scaltriti","is_ca":false},{"name":"Pieter J.A. Eichhorn","is_ca":false},{"name":"Javier Cortés","is_ca":false},{"name":"Ludmila Prudkin","is_ca":false},{"name":"Claudia Aura","is_ca":false},{"name":"José Jimenez","is_ca":false},{"name":"Sarat Chandarlapaty","is_ca":false},{"name":"Violeta Serra","is_ca":false},{"name":"Aleix Prat","is_ca":false},{"name":"Yasir H. Ibrahim","is_ca":false},{"name":"Marta Guzmán","is_ca":false},{"name":"Magüi Gili","is_ca":false},{"name":"Olga Rodríguez","is_ca":false},{"name":"Sónia Rodríguez","is_ca":false},{"name":"José Pérez","is_ca":false},{"name":"Simon R. Green","is_ca":false},{"name":"Sabine Mai","is_ca":true},{"name":"Neal Rosen","is_ca":false},{"name":"Clifford A. Hudis","is_ca":false},{"name":"José Baselga","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0794277388188846,"gpt":0.3594816967174915,"spread":0.2800539578986069,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001502126,0.00009252359,0.0002040897,0.0002120003,0.0001196978,0.0003415693,0.00009067866,0.000138298,0.0009947105],"category_scores_gemma":[0.0003163753,0.0001040411,0.0001094048,0.000282536,0.000112996,0.0001232743,0.0001068215,0.0002169139,0.0001747562],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001968857,"about_ca_system_score_gemma":0.0001068822,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003901686,"about_ca_topic_score_gemma":0.0004776521,"domain_scores_codex":[0.9999249,0.00001614934,0.000008548336,0.00001695347,0.00001698967,0.00001630885],"domain_scores_gemma":[0.9998866,0.00002414161,0.00004979735,0.000008816425,0.00001135265,0.00001928261],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002658532,0.0001828213,0.7931931,0.00006815082,0.00009343174,0.002667215,0.0001608342,0.0004769963,0.156284,0.0003099356,0.0007260615,0.04317886],"study_design_scores_gemma":[0.000088498,0.0008861764,0.9442764,0.0000114007,0.0001040443,0.0148162,0.0001721549,0.001824737,0.03289282,0.0002591168,0.004657448,0.00001101406],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9982167,0.0007896591,0.0001625199,0.00006269789,0.000002259296,0.000006707882,0.00006676013,0.000007992997,0.0006847467],"genre_scores_gemma":[0.9992734,0.0002338509,0.0001131586,0.0000323702,0.000006123269,0.000003420456,0.00009492008,0.000002005847,0.0002409079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0009947105,"threshold_uncertainty_score":0.003327668,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","authors":[{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Fabrice André","is_ca":false},{"name":"Zefei Jiang","is_ca":false},{"name":"Zhimin Shao","is_ca":false},{"name":"Max S. Mano","is_ca":false},{"name":"Silvia P. Neciosup","is_ca":false},{"name":"Ling-Min Tseng","is_ca":false},{"name":"Qingyuan Zhang","is_ca":false},{"name":"Kunwei Shen","is_ca":false},{"name":"Donggeng Liu","is_ca":false},{"name":"Lydia Dreosti","is_ca":false},{"name":"Howard A. Burris","is_ca":false},{"name":"Masakazu Toi","is_ca":false},{"name":"Marc Buyse","is_ca":false},{"name":"David Cabaribere","is_ca":false},{"name":"Mary-Ann Lindsay","is_ca":true},{"name":"Shantha Rao","is_ca":false},{"name":"Lida Pacaud","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1072753189955495,"gpt":0.4374998133184536,"spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001955015,0.002110032,0.0037827,0.0005106498,0.000401344,0.001534022,0.001366138,0.001999286,0.006876017],"category_scores_gemma":[0.001518939,0.0008662059,0.002318077,0.0004941671,0.00138514,0.001772876,0.0005771789,0.004396446,0.001468017],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009297517,"about_ca_system_score_gemma":0.001045478,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001160782,"about_ca_topic_score_gemma":0.003121152,"domain_scores_codex":[0.9994649,0.0002756144,0.00002739131,0.0001052924,0.00003458626,0.00009220523],"domain_scores_gemma":[0.9993445,0.0001718508,0.0001358959,0.00005718069,0.0000286863,0.0002617297],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9787768,0.004434233,0.0003524379,0.0006142916,0.001135787,0.00003248284,0.00005289801,0.0004422448,0.001528244,0.0001036667,0.001013771,0.01151331],"study_design_scores_gemma":[0.9610267,0.03674922,0.0008138993,0.00002812643,0.0003592927,0.00002726593,0.00001547123,0.0002420506,0.000160254,0.00009573939,0.0004689654,0.00001298408],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9781843,0.0112261,0.0007166324,0.00158832,0.001217722,0.002285277,0.001395701,0.0002465476,0.003139379],"genre_scores_gemma":[0.9726847,0.0082117,0.002129836,0.00246384,0.0008704535,0.00303294,0.002453577,0.00007356295,0.008079429],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006876017,"threshold_uncertainty_score":0.02300256,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2048686497","doi":"10.1200/jco.2003.12.109","title":"Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel","year":2003,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":296,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Trastuzumab; Medicine; Paclitaxel; Pharmacokinetics; Internal medicine; Adverse effect; Oncology; Metastatic breast cancer; Pharmacology; Breast cancer; Cancer","authors":[{"name":"Brian Leyland‐Jones","is_ca":true},{"name":"Karen A. Gelmon","is_ca":true},{"name":"Jean-Pierre Ayoub","is_ca":true},{"name":"Andrew Arnold","is_ca":true},{"name":"Shail Verma","is_ca":true},{"name":"Reg Dias","is_ca":true},{"name":"Parviz Ghahramani","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1723146508754793,"gpt":0.5133159105305432,"spread":0.3410012596550639,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000412247,0.0003507382,0.0005883073,0.0002302721,0.0001690341,0.0003804682,0.0003320941,0.0002920361,0.0006054856],"category_scores_gemma":[0.0009250679,0.0002558061,0.0002577836,0.0002313765,0.0003457086,0.0002124042,0.00008848491,0.0007655947,0.0002303516],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000431206,"about_ca_system_score_gemma":0.0004148067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004229217,"about_ca_topic_score_gemma":0.0004705272,"domain_scores_codex":[0.9996924,0.0001430524,0.00001322362,0.00004353343,0.00006068878,0.00004706045],"domain_scores_gemma":[0.9996579,0.00009150613,0.0001146977,0.00002532114,0.00001663937,0.00009395465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2122714,0.02548718,0.05349952,0.0003100711,0.0005864855,0.0007972452,0.0004591885,0.009196633,0.3696864,0.0001665779,0.001603623,0.3259357],"study_design_scores_gemma":[0.1012952,0.5641434,0.1769545,0.00009805046,0.000834563,0.003641573,0.0001864668,0.02045173,0.12386,0.0003347961,0.008104836,0.00009490444],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9985166,0.0007378031,0.0002953573,0.00003614428,0.000009674838,0.00006122354,0.00002420303,0.00002445383,0.000294493],"genre_scores_gemma":[0.9988776,0.000250128,0.0003564886,0.00004240737,0.00002134112,0.00008006688,0.0001057486,0.000009411793,0.0002568155],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0006054856,"threshold_uncertainty_score":0.003128648,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948726637","doi":"10.1016/s0140-6736(19)30650-6","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","year":2019,"lang":"en","type":"article","venue":"The Lancet","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Health Economics","funders":"Health Technology Assessment Programme; National Institute for Health and Care Research; University of Warwick; Cancer Research UK; University of Cambridge; Department of Health and Social Care","keywords":"Medicine; Trastuzumab; Breast cancer; Clinical endpoint; Internal medicine; Intention-to-treat analysis; Surgery; Randomized controlled trial; Clinical trial; Chemotherapy; Adjuvant; Cancer; Oncology","authors":[{"name":"Helena Earl","is_ca":false},{"name":"Louise Hiller","is_ca":false},{"name":"Anne-Laure Vallier","is_ca":false},{"name":"Shrushma Loi","is_ca":false},{"name":"Karen McAdam","is_ca":false},{"name":"Luke Hughes‐Davies","is_ca":false},{"name":"Adrian Harnett","is_ca":false},{"name":"Mei-Lin Ah-See","is_ca":false},{"name":"Richard Simcock","is_ca":false},{"name":"Daniel Rea","is_ca":false},{"name":"Sanjay Raj","is_ca":false},{"name":"Pamela Woodings","is_ca":false},{"name":"Mark Harries","is_ca":false},{"name":"Donna Howe","is_ca":false},{"name":"Kerry Raynes","is_ca":false},{"name":"Helen Higgins","is_ca":false},{"name":"Maggie Wilcox","is_ca":false},{"name":"Chris Plummer","is_ca":false},{"name":"Janine Mansi","is_ca":false},{"name":"Ioannis Gounaris","is_ca":false},{"name":"Betania Mahler‐Araujo","is_ca":false},{"name":"Elena Provenzano","is_ca":false},{"name":"Anita Chhabra","is_ca":false},{"name":"Jean Abraham","is_ca":false},{"name":"Carlos Caldas","is_ca":false},{"name":"Peter S Hall","is_ca":false},{"name":"Christopher McCabe","is_ca":true},{"name":"Claire Hulme","is_ca":false},{"name":"David Miles","is_ca":false},{"name":"Andrew Wardley","is_ca":false},{"name":"David Cameron","is_ca":false},{"name":"Janet Dunn","is_ca":false},{"name":"Roshan Agarwal","is_ca":false},{"name":"Hafiz Algurafi","is_ca":false},{"name":"R. Allerton","is_ca":false},{"name":"Caroline Archer","is_ca":false},{"name":"Anne Armstrong","is_ca":false},{"name":"C. Bale","is_ca":false},{"name":"Lisa Barraclough","is_ca":false},{"name":"U. Barthakur","is_ca":false},{"name":"C. Bedi","is_ca":false},{"name":"Kim Benstead","is_ca":false},{"name":"David Bloomfield","is_ca":false},{"name":"Rebecca Bowen","is_ca":false},{"name":"Chris Bradley","is_ca":true},{"name":"Jane Brown","is_ca":false},{"name":"Mohammad Butt","is_ca":false},{"name":"Mark Churn","is_ca":false},{"name":"Susan Cleator","is_ca":false},{"name":"Joanne Cliff","is_ca":false},{"name":"Perric Crellin","is_ca":false},{"name":"Margaret Daly","is_ca":false},{"name":"Shiroma De Silva-Minor","is_ca":false},{"name":"A.S. Dhadda","is_ca":false},{"name":"Omar Din","is_ca":false},{"name":"Sue Down","is_ca":false},{"name":"David Eaton","is_ca":false},{"name":"Andrew Eichholz","is_ca":false},{"name":"Daniel Epurescu","is_ca":false},{"name":"Chee Goh","is_ca":false},{"name":"Andrew Goodman","is_ca":false},{"name":"Robert Grieve","is_ca":false},{"name":"Maher Hadaki","is_ca":false},{"name":"Catherine Harper‐Wynne","is_ca":false},{"name":"Larry Hayward","is_ca":false},{"name":"Alison Humphreys","is_ca":false},{"name":"Helen Innes","is_ca":false},{"name":"Mariam Jafri","is_ca":false},{"name":"A. Jegannathen","is_ca":false},{"name":"Muireann Kelleher","is_ca":false},{"name":"Hartmut Kristeleit","is_ca":false},{"name":"Daniela Lee","is_ca":false},{"name":"Susan Lupton","is_ca":false},{"name":"Carol MacGregor","is_ca":false},{"name":"Zafar Malik","is_ca":false},{"name":"Jennifer Marshall","is_ca":false},{"name":"Trevor McGolick","is_ca":false},{"name":"Rakesh Mehra","is_ca":false},{"name":"Natasha Mithal","is_ca":false},{"name":"Charlotte Moss","is_ca":false},{"name":"Mukesh Mukesh","is_ca":false},{"name":"Anthony Neal","is_ca":false},{"name":"D. Nelmes","is_ca":false},{"name":"Helen Neville-Webbe","is_ca":false},{"name":"Jacqueline C. Newby","is_ca":false},{"name":"Peter Ostler","is_ca":false},{"name":"Mojca Persic","is_ca":false},{"name":"Laura Pettit","is_ca":false},{"name":"Fharat Raja","is_ca":false},{"name":"Catherine Reed","is_ca":false},{"name":"Anne Rigg","is_ca":false},{"name":"Helen Roe","is_ca":false},{"name":"Nihal Shah","is_ca":false},{"name":"Peter Simmonds","is_ca":false},{"name":"Eliot Sims","is_ca":false},{"name":"Sarah Smith","is_ca":false},{"name":"Nicola Storey","is_ca":false},{"name":"W. Chris Taylor","is_ca":false},{"name":"Narottam Thanvi","is_ca":false},{"name":"Karen Tipples","is_ca":false},{"name":"Jayant S. Vaidya","is_ca":false},{"name":"Mohini Varughese","is_ca":false},{"name":"Anup Vinayan","is_ca":false},{"name":"Nawaz Walji","is_ca":false},{"name":"Simon Waters","is_ca":false},{"name":"Kathryn Wright","is_ca":false},{"name":"Sundus Yahya","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05371163214208088,"gpt":0.3732203289132454,"spread":0.3195086967711646,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004834649,0.001482618,0.00221702,0.0004107205,0.0003334876,0.0008789535,0.0007725456,0.002075213,0.007191629],"category_scores_gemma":[0.004164773,0.0004752815,0.002619363,0.000360225,0.001195799,0.00113992,0.0004397056,0.002249701,0.0008604209],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006914245,"about_ca_system_score_gemma":0.0009132443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000486859,"about_ca_topic_score_gemma":0.0009970089,"domain_scores_codex":[0.9981486,0.00132861,0.00009070165,0.0001782622,0.00008614273,0.0001677965],"domain_scores_gemma":[0.9974833,0.001068543,0.0006819596,0.0002004587,0.00009801025,0.0004677502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9873915,0.002852875,0.0002893661,0.0003016664,0.0004477734,0.00002266445,0.00004061605,0.0001940787,0.0008810314,0.00004292107,0.0002544478,0.007281095],"study_design_scores_gemma":[0.9508998,0.04678125,0.001241459,0.00003686098,0.0003186125,0.00002428542,0.00001089243,0.0001800976,0.0001513794,0.0001159135,0.0002299401,0.000009598333],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877743,0.004984865,0.0005601247,0.000715517,0.0003890019,0.003088222,0.0006676619,0.00005883494,0.001761461],"genre_scores_gemma":[0.9835839,0.002988972,0.001552822,0.001396329,0.0005551768,0.005448194,0.0008209709,0.00003364786,0.003620094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007191629,"threshold_uncertainty_score":0.02556837,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2774227900","doi":"10.1016/j.ejca.2017.10.021","title":"Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer","year":2017,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":283,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; University of British Columbia","funders":"F. Hoffmann-La Roche; Roche","keywords":"Pertuzumab; Anthracycline; Trastuzumab; Medicine; Oncology; Internal medicine; Chemotherapy; Cancer; Breast cancer","authors":[{"name":"Andreas Schneeweiß","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"Tamas Hickish","is_ca":false},{"name":"Vernon Harvey","is_ca":false},{"name":"Alexandru Eniu","is_ca":false},{"name":"Maeve Waldron-Lynch","is_ca":false},{"name":"Jennifer Eng‐Wong","is_ca":false},{"name":"S Kirk","is_ca":false},{"name":"Javier Cortés","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02363119783183756,"gpt":0.3797801121478566,"spread":0.356148914316019,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005872987,0.002131372,0.003644009,0.0005068023,0.0006460848,0.001880585,0.001433719,0.002561379,0.005252973],"category_scores_gemma":[0.005382767,0.0009817722,0.003677592,0.0005866233,0.002436698,0.002116632,0.001000219,0.005313793,0.00131742],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001464947,"about_ca_system_score_gemma":0.001575722,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001045086,"about_ca_topic_score_gemma":0.002024158,"domain_scores_codex":[0.9968798,0.001952795,0.0001318682,0.0004523935,0.0002149671,0.0003681323],"domain_scores_gemma":[0.9943951,0.001606119,0.001385755,0.0007097399,0.0003364938,0.00156671],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9830385,0.004632908,0.001902448,0.0001361725,0.001700107,0.0000350872,0.00005498303,0.000451557,0.001960589,0.00006675999,0.0004801555,0.005540653],"study_design_scores_gemma":[0.8896674,0.09666484,0.01046166,0.00001772735,0.001547691,0.00005858634,0.00003982459,0.0004036259,0.0003933706,0.0001758572,0.0005384071,0.00003102797],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932051,0.001809768,0.0005683387,0.0004879624,0.0002051402,0.0009098698,0.001362005,0.00006669525,0.001385087],"genre_scores_gemma":[0.99123,0.0008410622,0.0007499043,0.0009197471,0.0005023105,0.00129605,0.002593293,0.00003900273,0.001828644],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005872987,"threshold_uncertainty_score":0.03105968,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2012505736","doi":"10.1038/modpathol.2013.103","title":"HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity","year":2013,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":282,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"National Institute for Health and Care Research","keywords":"Polysomy; Trastuzumab; Breast cancer; Genetic heterogeneity; Fluorescence in situ hybridization; Chromosome 17 (human); Cancer; Biology; Oncology; Pathology; Internal medicine; Chromosome; Medicine; Genetics; Phenotype; Gene","authors":[{"name":"Wedad Hanna","is_ca":true},{"name":"Josef Rüschoff","is_ca":false},{"name":"Michael Bilous","is_ca":false},{"name":"Renata A. Coudry","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"R. Yoshiyuki Osamura","is_ca":false},{"name":"Frédérique Penault‐Llorca","is_ca":false},{"name":"Marc J. van de Vijver","is_ca":false},{"name":"Giuseppe Viale","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1485677386235298,"gpt":0.48226546491079,"spread":0.3336977262872602,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008543452,0.0006763941,0.001275476,0.002667006,0.0001378665,0.0007774675,0.0009147104,0.0008190056,0.001551864],"category_scores_gemma":[0.001277981,0.0002442282,0.0003977804,0.00251055,0.0005501154,0.001194956,0.0006614314,0.001027533,0.0006662536],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005706539,"about_ca_system_score_gemma":0.001091431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001186101,"about_ca_topic_score_gemma":0.002484503,"domain_scores_codex":[0.9997222,0.00004612233,0.00004277925,0.00006508479,0.0001002887,0.00002345809],"domain_scores_gemma":[0.9992954,0.0004239926,0.00009378794,0.00001402077,0.0001326492,0.00004011381],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00005091882,0.00001808949,0.0007690295,0.00800597,0.00009246828,0.0005798499,0.0000410965,0.0002061115,0.001249166,0.001404256,0.01649293,0.9710901],"study_design_scores_gemma":[0.0000285981,0.00008339829,0.004832524,0.007236519,0.0005712837,0.01017064,0.0002551012,0.0001893178,0.0009409307,0.003657077,0.9719799,0.00005472733],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001305571,0.9990374,0.000110294,0.0002427712,0.00009602599,0.000001457826,0.00001263171,0.000003686898,0.0003653053],"genre_scores_gemma":[0.001045351,0.998129,0.0001922141,0.0002179762,0.0001924028,0.00000209333,0.00002649595,0.00000133019,0.0001931696],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002667006,"threshold_uncertainty_score":0.005191505,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2158179945","doi":"10.1016/s1470-2045(03)01137-9","title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","year":2003,"lang":"en","type":"review","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":281,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Queen's University; University Health Network; University of Toronto","funders":"Cancer Research Society; American Association for Cancer Research","keywords":"Erlotinib; Gefitinib; Cetuximab; Epidermal growth factor receptor; Medicine; Lung cancer; Amphiregulin; Cancer research; Epidermal growth factor; Tyrosine kinase; Cancer; Carcinogenesis; Trastuzumab; Oncology; Receptor; Internal medicine; Colorectal cancer; Breast cancer","authors":[{"name":"Srikala S. Sridhar","is_ca":true},{"name":"Lesley Seymour","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.3917200543381659,"gpt":0.5739504872546254,"spread":0.1822304329164595,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001075508,0.001339114,0.003805761,0.003485259,0.0002633239,0.001321201,0.001383705,0.001503761,0.003245525],"category_scores_gemma":[0.00126512,0.0003573586,0.0009522502,0.004961019,0.0004796901,0.001633128,0.0005940362,0.001866665,0.001533551],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009511952,"about_ca_system_score_gemma":0.001644309,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002073752,"about_ca_topic_score_gemma":0.005945717,"domain_scores_codex":[0.9996449,0.00006148045,0.00006578351,0.00005733397,0.0001433919,0.00002715879],"domain_scores_gemma":[0.9992262,0.0004164919,0.0001185507,0.0000146083,0.0001677629,0.0000564644],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002674523,0.00009268097,0.0001455187,0.0409745,0.0002793859,0.0002608814,0.00005073793,0.0003677433,0.001598978,0.001472856,0.06305405,0.8914353],"study_design_scores_gemma":[0.0001922395,0.0002791893,0.00119819,0.01343648,0.000812893,0.001614105,0.0001087627,0.0001423113,0.0004156536,0.001278778,0.9804834,0.00003798066],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00004716542,0.99932,0.00005771426,0.0001375489,0.0001516711,0.000005364736,0.00001741579,0.000005358836,0.0002576883],"genre_scores_gemma":[0.0002390055,0.9990407,0.0001606188,0.0002111512,0.0001008928,0.000005061541,0.0000259453,9.353182e-7,0.0002156656],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003805761,"threshold_uncertainty_score":0.0108574,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2071130163","doi":"10.1097/01.mp.0000052102.90815.82","title":"Current Perspectives on HER2 Testing: A Review of National Testing Guidelines","year":2003,"lang":"en","type":"review","venue":"Modern Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":269,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Health Science Centre; Women's College Hospital; University of Toronto","funders":"","keywords":"Medicine; Medical physics; Quality assurance; Trastuzumab; Pathology; Test (biology); Fish <Actinopterygii>; External quality assessment; Intensive care medicine; Internal medicine; Breast cancer; Cancer; Biology","authors":[{"name":"Michael Bilous","is_ca":false},{"name":"Mitch Dowsett","is_ca":false},{"name":"Wedad Hanna","is_ca":true},{"name":"Jorma Isola","is_ca":false},{"name":"Annette Lebeau","is_ca":false},{"name":"Aberlardo Moreno","is_ca":false},{"name":"Frédérique Penault‐Llorca","is_ca":false},{"name":"Josef Rüschoff","is_ca":false},{"name":"Gorana Tomasic","is_ca":false},{"name":"Marc J. van de Vijver","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.5663146011887417,"gpt":0.5638883755037888,"spread":0.002426225684952876,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003979109,0.0009326809,0.002992687,0.00433495,0.000413497,0.001645021,0.001897373,0.002128962,0.004147075],"category_scores_gemma":[0.006944489,0.0004122167,0.000965645,0.005973506,0.0008195637,0.00265899,0.0009482445,0.002447445,0.001555578],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001985827,"about_ca_system_score_gemma":0.00476393,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005238073,"about_ca_topic_score_gemma":0.01406038,"domain_scores_codex":[0.9989135,0.0002545903,0.0002676118,0.0001440356,0.0003645471,0.00005574917],"domain_scores_gemma":[0.9931374,0.004483766,0.0006971428,0.00009711698,0.001361488,0.0002232286],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001308507,0.00005951977,0.0004905254,0.02025675,0.0001312638,0.0003397612,0.00008194826,0.0002807969,0.0004051005,0.002202023,0.08894155,0.8866799],"study_design_scores_gemma":[0.00006979429,0.00009488692,0.002559843,0.02919381,0.0006072806,0.001859956,0.0002249368,0.0001635018,0.0002817672,0.002397304,0.9625049,0.0000421302],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006233329,0.9974951,0.000117205,0.001530284,0.0002176229,0.000003493299,0.00002914862,0.000006004263,0.0005389319],"genre_scores_gemma":[0.0003551501,0.9979996,0.0002971981,0.0009103681,0.0002349979,0.000006591245,0.00004024951,0.000001441377,0.0001543912],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005238073,"threshold_uncertainty_score":0.02104378,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2163167967","doi":"10.1136/jclinpath-2014-202571","title":"Updated UK Recommendations for HER2 assessment in breast cancer","year":2014,"lang":"en","type":"article","venue":"Journal of Clinical Pathology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":259,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research; Ontario Institute for Cancer Research","funders":"","keywords":"Breast cancer; Medicine; Bioinformatics; Oncology; Medical physics; Cancer; Internal medicine; Biology","authors":[{"name":"Emad A. Rakha","is_ca":false},{"name":"Sarah E. Pinder","is_ca":false},{"name":"John M.S. Bartlett","is_ca":true},{"name":"Merdol Ibrahim","is_ca":false},{"name":"Jane Starczynski","is_ca":false},{"name":"P J Carder","is_ca":false},{"name":"Elena Provenzano","is_ca":false},{"name":"Andrew M. Hanby","is_ca":false},{"name":"S Hales","is_ca":false},{"name":"Andrew H.S. Lee","is_ca":false},{"name":"Ian O. Ellis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1850342865328451,"gpt":0.5861699026089259,"spread":0.4011356160760807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01031047,0.00102996,0.001850598,0.005713542,0.0009071308,0.00255113,0.004438655,0.006566778,0.02108801],"category_scores_gemma":[0.04670572,0.000849588,0.002825428,0.005331444,0.001272614,0.002217983,0.002663564,0.006176384,0.01628158],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005016552,"about_ca_system_score_gemma":0.009806765,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.03093532,"about_ca_topic_score_gemma":0.03793961,"domain_scores_codex":[0.986796,0.004974219,0.002986896,0.0003887585,0.00413608,0.0007181051],"domain_scores_gemma":[0.9530657,0.00840288,0.003901566,0.001233303,0.03143612,0.001960403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006388542,0.00007094309,0.000808868,0.001495644,0.00002390675,0.0002691059,0.0001539748,0.0002510375,0.0002084241,0.001132858,0.8440601,0.1514612],"study_design_scores_gemma":[0.0000722394,0.00006299277,0.002845577,0.005462837,0.0000500612,0.0006757477,0.0001723276,0.0001393228,0.0001377795,0.001394196,0.988946,0.00004093611],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.003251958,0.2654861,0.0185023,0.4393367,0.05230609,0.004121842,0.02046188,0.002659194,0.1938739],"genre_scores_gemma":[0.02462862,0.3120416,0.1796053,0.2159701,0.0115567,0.01070675,0.05633167,0.001170854,0.1879883],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.03093532,"threshold_uncertainty_score":0.07054639,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1988557714","doi":"10.1016/j.ctrv.2003.10.002","title":"Epidermal growth factor receptor: a promising target in solid tumours","year":2003,"lang":"en","type":"review","venue":"Cancer Treatment Reviews","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Epidermal growth factor receptor; Monoclonal antibody; Tyrosine kinase; Cancer research; Cancer; Receptor tyrosine kinase; Signal transduction; Targeted therapy; EGFR inhibitors; Cetuximab; Blockade; Pharmacology; Receptor; Immunology; Antibody; Internal medicine; Biology; Cell biology","authors":[{"name":"Janessa Laskin","is_ca":true},{"name":"Alan B. Sandler","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2218575342477881,"gpt":0.4851877966864617,"spread":0.2633302624386736,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008243148,0.001302378,0.002100687,0.002234166,0.0003249283,0.001255317,0.0007927023,0.001455836,0.005071239],"category_scores_gemma":[0.0006433449,0.0003013682,0.0005050566,0.002792013,0.0004452218,0.001646513,0.0005304638,0.001816904,0.003655473],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008262415,"about_ca_system_score_gemma":0.001274695,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00116896,"about_ca_topic_score_gemma":0.00318953,"domain_scores_codex":[0.99977,0.0000371835,0.00002943096,0.00003576421,0.0001045549,0.00002312716],"domain_scores_gemma":[0.9997097,0.0001285855,0.00004406911,0.000008335453,0.00007521982,0.00003415187],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001552033,0.0000891942,0.0001190776,0.01052484,0.00008729262,0.0003670694,0.00003574131,0.0003236285,0.00305092,0.001829484,0.08130823,0.9021094],"study_design_scores_gemma":[0.00005147743,0.0001439147,0.0004415362,0.001554084,0.0001650997,0.001391597,0.00004202003,0.00007168593,0.0005234434,0.0007465497,0.9948556,0.0000129106],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001210416,0.9971686,0.0001786034,0.0004042624,0.0005117049,0.000007423606,0.00002676645,0.0000120509,0.001569624],"genre_scores_gemma":[0.0004926945,0.9971521,0.0002340142,0.0003706818,0.0003045674,0.000008307701,0.0000415741,0.000001884358,0.001394186],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005071239,"threshold_uncertainty_score":0.01696503,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2013797830","doi":"10.1186/bcr2904","title":"Luminal-B breast cancer and novel therapeutic targets","year":2011,"lang":"en","type":"review","venue":"Breast Cancer Research","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":249,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Breast cancer; Surgical oncology; Estrogen receptor; Medicine; Cancer research; Gene expression profiling; Bioinformatics; Pathological; Endocrine system; Oncology; Cancer; Internal medicine; Gene; Gene expression; Biology; Hormone; Genetics","authors":[{"name":"Ben Tran","is_ca":true},{"name":"Philippe L. Bédard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.289696687158721,"gpt":0.5148012716975511,"spread":0.2251045845388301,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004877118,0.0007150982,0.001335739,0.001960268,0.0002413718,0.0007957933,0.0007726479,0.0009255983,0.00341066],"category_scores_gemma":[0.0005121461,0.0002527575,0.0003896011,0.00162435,0.0003995548,0.001119082,0.0004900178,0.002002979,0.002319338],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006920245,"about_ca_system_score_gemma":0.0006493711,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006823653,"about_ca_topic_score_gemma":0.00165709,"domain_scores_codex":[0.9998409,0.00003394624,0.00001900404,0.00002661134,0.00006157972,0.0000179436],"domain_scores_gemma":[0.9998561,0.00005713591,0.00001985342,0.000005621157,0.00004522125,0.00001598468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00007100823,0.0001325109,0.0001235783,0.007489764,0.00005934136,0.0004254004,0.00004346296,0.0004730775,0.002310303,0.003983081,0.03907429,0.9458141],"study_design_scores_gemma":[0.00003291425,0.00009872568,0.0006392073,0.002665962,0.00005662308,0.002319199,0.00005030843,0.0001247441,0.0005435383,0.002175362,0.991277,0.00001647678],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001125505,0.9981322,0.0001128054,0.0003593969,0.0001450471,0.00000423812,0.00001275194,0.000007197023,0.001113759],"genre_scores_gemma":[0.0006964637,0.9979395,0.0001844826,0.0002516257,0.0001346682,0.000006914544,0.00002773329,0.000001362313,0.0007571233],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.00341066,"threshold_uncertainty_score":0.01140982,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948405934","doi":"10.1200/jco.19.00882","title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":248,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"National Cancer Institute; American Society of Clinical Oncology","keywords":"Pertuzumab; Medicine; Trastuzumab emtansine; Internal medicine; Hazard ratio; Trastuzumab; Oncology; Breast cancer; Docetaxel; Adverse effect; Cancer; Surgery; Confidence interval","authors":[{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Kyung Hae Jung","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Nadia Harbeck","is_ca":false},{"name":"Vicente Valero","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Hans Wildiers","is_ca":false},{"name":"Mario Campone","is_ca":false},{"name":"Jean-François Boileau","is_ca":true},{"name":"Peter A. Fasching","is_ca":false},{"name":"Karen Afenjar","is_ca":false},{"name":"Gonzalo Spera","is_ca":false},{"name":"Vanesa López-Valverde","is_ca":false},{"name":"Chunyan Song","is_ca":false},{"name":"Peter C. Trask","is_ca":false},{"name":"Thomas Boulet","is_ca":false},{"name":"Joseph A. Sparano","is_ca":false},{"name":"W. Fraser Symmans","is_ca":false},{"name":"Alastair M. Thompson","is_ca":false},{"name":"Dennis J. Slamon","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1404453096150034,"gpt":0.5111550693327782,"spread":0.3707097597177748,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002409769,0.0005789014,0.001184018,0.0001947231,0.0002599707,0.0007228457,0.0004330045,0.0006046284,0.0008020871],"category_scores_gemma":[0.001214951,0.0002228182,0.00147628,0.0002849874,0.0004054499,0.0005106172,0.0003654435,0.001105325,0.0001694849],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006713197,"about_ca_system_score_gemma":0.0007868558,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001138066,"about_ca_topic_score_gemma":0.003528629,"domain_scores_codex":[0.9992076,0.0004635355,0.00005000276,0.00007817226,0.000116838,0.00008385299],"domain_scores_gemma":[0.9988816,0.0002182072,0.0003988604,0.0001180459,0.00006957082,0.000313657],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7894419,0.01518983,0.07154462,0.001000544,0.006278976,0.0002471014,0.0002775949,0.004472166,0.01048358,0.000244575,0.004728026,0.09609105],"study_design_scores_gemma":[0.3393111,0.3024053,0.3297013,0.000248404,0.009017034,0.0008636037,0.0002927934,0.003599746,0.005408572,0.0004361456,0.008601124,0.0001149685],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940552,0.003564417,0.0002081806,0.0001867071,0.00004056974,0.0002891404,0.0007729915,0.0000139825,0.0008688068],"genre_scores_gemma":[0.9931398,0.002234387,0.0003849454,0.0003990112,0.00009314045,0.0003541187,0.002533225,0.000009348596,0.000852122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002409769,"threshold_uncertainty_score":0.01274425,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2556607246","doi":"10.5858/arpa.2016-0331-cp","title":"HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","year":2016,"lang":"en","type":"article","venue":"Archives of Pathology & Laboratory Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":246,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Guideline; Clinical Oncology; Internal medicine; Adenocarcinoma; Biomarker; Clinical pathology; Oncology; Pathology; Cancer","authors":[{"name":"Angela N. Bartley","is_ca":false},{"name":"M. Kay Washington","is_ca":false},{"name":"Christina B. Ventura","is_ca":false},{"name":"Nofisat Ismaila","is_ca":false},{"name":"Carol Colasacco","is_ca":false},{"name":"Al B. Benson","is_ca":false},{"name":"Alfredo Carrato","is_ca":false},{"name":"Margaret L. Gulley","is_ca":false},{"name":"Dhanpat Jain","is_ca":false},{"name":"Sanjay Kakar","is_ca":false},{"name":"Helen Mackay","is_ca":true},{"name":"Catherine Streutker","is_ca":true},{"name":"Laura H. Tang","is_ca":false},{"name":"Megan L. Troxell","is_ca":false},{"name":"Jaffer A. Ajani","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1289693971999853,"gpt":0.4916737082039777,"spread":0.3627043110039924,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03260398,0.001733621,0.002652574,0.005328234,0.001831745,0.003548526,0.007038939,0.01041811,0.003081932],"category_scores_gemma":[0.08216649,0.00116344,0.00575988,0.005047888,0.002039227,0.003546731,0.003502419,0.01113174,0.002752162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.008074791,"about_ca_system_score_gemma":0.03252098,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.02676364,"about_ca_topic_score_gemma":0.04951863,"domain_scores_codex":[0.9624736,0.0198049,0.008775497,0.001228581,0.006839802,0.0008776521],"domain_scores_gemma":[0.93287,0.02220467,0.008652298,0.0010617,0.03185793,0.003353362],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001206483,0.0001518085,0.001707635,0.01283777,0.0004338149,0.0003876011,0.0006439707,0.001187781,0.0003076283,0.004910772,0.7835465,0.193764],"study_design_scores_gemma":[0.001019901,0.000255612,0.007207725,0.1723263,0.002092142,0.001251106,0.0008924176,0.002476307,0.000555445,0.02074733,0.7909256,0.0002500239],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.002413532,0.2929202,0.01529012,0.6377838,0.01492911,0.005401826,0.004897001,0.0004260959,0.02593839],"genre_scores_gemma":[0.03560003,0.4207586,0.2081963,0.2833951,0.01066092,0.01341431,0.01528496,0.0002789565,0.01241091],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.03260398,"threshold_uncertainty_score":0.1724284,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2091242368","doi":"10.1172/jci57100","title":"Breast cancer — one term, many entities?","year":2011,"lang":"en","type":"review","venue":"Journal of Clinical Investigation","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; McGill University Health Centre","funders":"McGill University Health Centre; McGill University","keywords":"Breast cancer; Cancer; Breast tumor; Disease; Computational biology; Bioinformatics; Medicine; Tumor heterogeneity; Biology; Cancer research; Pathology; Internal medicine","authors":[{"name":"Nicholas Bertos","is_ca":true},{"name":"Morag Park","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.4923396356444193,"gpt":0.5576649504711761,"spread":0.06532531482675685,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007711712,0.0008608371,0.001791378,0.002103092,0.0004437294,0.001724608,0.0009738634,0.001327831,0.002537971],"category_scores_gemma":[0.001415651,0.0002465928,0.0003317176,0.002878785,0.001490805,0.004002891,0.001082544,0.00280158,0.002518975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001066785,"about_ca_system_score_gemma":0.001575135,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001363927,"about_ca_topic_score_gemma":0.002458247,"domain_scores_codex":[0.9996124,0.0001174663,0.00004904908,0.00005395724,0.0001320487,0.00003506373],"domain_scores_gemma":[0.9994296,0.0002458907,0.00006079005,0.00003155386,0.0001563762,0.00007571506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006048635,0.00003915354,0.0004154319,0.004423095,0.00006138792,0.0003736319,0.0001588996,0.0001437511,0.0007731897,0.01081153,0.1767978,0.8059416],"study_design_scores_gemma":[0.000006586939,0.00002153994,0.0004096111,0.001923915,0.0000286639,0.002579988,0.0002148483,0.00003082348,0.00007646936,0.005031503,0.9896646,0.00001145876],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007903194,0.9937732,0.0001328894,0.003340186,0.001220212,0.00000232542,0.00001030551,0.000008753808,0.001433093],"genre_scores_gemma":[0.001298307,0.9924365,0.0003463969,0.002405806,0.001888294,0.000005549631,0.00002842895,0.000003738182,0.00158699],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002537971,"threshold_uncertainty_score":0.008490324,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2277879584","doi":"10.1007/s40259-016-0162-9","title":"Trastuzumab in the Treatment of Breast Cancer","year":2016,"lang":"en","type":"review","venue":"BioDrugs","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Norwegian Institute of Public Health; Direktorat Jenderal Pendidikan Tinggi; Sanofi Pasteur; Johns Hopkins Bloomberg School of Public Health; University of Illinois at Urbana-Champaign; National Institutes of Health; Seqirus; Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja; Ministero della Salute; National Health and Medical Research Council; AstraZeneca; Amarin Corporation; Bundesministerium für Bildung und Forschung; Novavax; Sanofi; Comunidad de Madrid; Boston Scientific Corporation; Public Health England; University of Calgary; Arizona State University; GlaxoSmithKline; Bristol-Myers Squibb; Australian Government; Pfizer; Lembaga Pengelola Dana Pendidikan; Johns Hopkins University; Edwards Lifesciences; Bill and Melinda Gates Foundation; Instituto de Salud Carlos III; Amgen; Damon Runyon Cancer Research Foundation; Medical Research Council; Teva Pharmaceutical Industries; South African Medical Research Council; Seoul National University; U.S. Department of Veterans Affairs; Genentech; U.S. Environmental Protection Agency","keywords":"Trastuzumab; Pertuzumab; Medicine; Lapatinib; Breast cancer; Cardiotoxicity; Cancer; Disease; Oncology; Targeted therapy; Internal medicine; Pharmacology; Chemotherapy","authors":[{"name":"Sofia Maximiano","is_ca":false},{"name":"Paulo Magalhães","is_ca":false},{"name":"Mara Pereira Guerreiro","is_ca":false},{"name":"Manuel Morgado","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1386676677073322,"gpt":0.4761857603569551,"spread":0.337518092649623,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006767204,0.0009088516,0.001931957,0.002399624,0.0002084013,0.0009851636,0.0008751166,0.001013978,0.003541812],"category_scores_gemma":[0.0009819958,0.0002909772,0.0006017548,0.002257132,0.0004104078,0.001080005,0.0007754232,0.001858872,0.001155809],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006616839,"about_ca_system_score_gemma":0.0009574449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001541525,"about_ca_topic_score_gemma":0.003536819,"domain_scores_codex":[0.9997869,0.00004355324,0.000035773,0.00003232361,0.00007680229,0.00002476676],"domain_scores_gemma":[0.9996655,0.0001819338,0.00005888785,0.000007706467,0.00005941229,0.00002656684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001350024,0.00006698688,0.0001042216,0.02259624,0.0001654534,0.0001403438,0.00003863789,0.000385366,0.001092793,0.002271991,0.02202445,0.9509786],"study_design_scores_gemma":[0.00009430505,0.0001581364,0.0006934064,0.008471993,0.0004427209,0.0009588999,0.00005440756,0.0001519404,0.0004877443,0.001736134,0.9867284,0.00002192408],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005737072,0.9993703,0.00003892804,0.0001090942,0.00008602891,0.00000266685,0.000009374323,0.000002510406,0.0003237922],"genre_scores_gemma":[0.0004396165,0.998989,0.0000625571,0.0001342859,0.00008559346,0.000002738562,0.00001608973,6.65057e-7,0.0002693653],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.003541812,"threshold_uncertainty_score":0.01184851,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}